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Cancers of the oesophagus, stomach and pancreas referred to collectively as upper
gastro-intestinal (GI) cancers leads to 18,250 deaths in England and Wales per year,
or 13.5% of all cancer deaths'. Currently, gastric cancer alone is the fourth
commonest cause of death from cancer in the UK, after cancer of the lung, colon and
rectum, and breast . Worldwide it remains the second most common cause of death
from malignant disease .
Over recent years the incidence of oesophageal and gastric cancers has been
changing. For more than half a century the overall incidence and mortality rates for
gastric cancer has been slowly declining 4 but recently adenocarcinoma (ACA) of the
f o
t
gastric cardia has become more common " . Similarly, adenocarcinoma of the
oesophagus is also becoming more prevalent so that it is now the commonest form of
oesophageal cancer9'9"12. For these reasons the emphasis for this thesis will be
adenocarcinoma of the oesophagus and stomach (figures 1.1-1.4) rather than the less
common forms of oesophago-gastric cancer.
Unfortunately, the 5-year survival for patients with oesophageal cancer in England is
only around 9% and for those with gastric cancer it is only around 12%. Not
surprisingly these patients often consider such a diagnosis as a virtual death sentence.
This plight is not universal, indeed within Western Europe and worldwide these
13 • •
patients can have a much better prognosis . We must therefore identify, and
understand, why this is the case ifwe are to improve the outcome for these patients
in the UK.
1.2 Epidemiology and aetiology.
Although a disease of the elderly the majority of patients are aged less than 75 years.
These cancers are diagnosed in 1 in 100,000 people under the age of 40, 20 per
100.000 in those aged 45-54 and 155 per 100,000 in those over 551.
1.3 Pathogenesis of oesophageal cancer
1.3.1 Environmental and dietary agents in oesophageal cancer.
Both alcohol and tobacco consumption can act independently and synergistically to
increase the risk of both squamous and adenocarcinoma of the oesophagus, although
the increase is greater for squamous cell carcinomas l4. A French case-control study
found a relative risk (RR) of oesophageal cancer among non-smokers in the highest
category of alcohol use (>57 u/week) of 5.1, compared with non-smokers who drank
least; for those in the highest tobacco use category (20 cigarettes per day) the RR was
18.0; but among those in both highest categories the RR was 44.4l5. This has also
been shown in a number of other studies from both Eastern and Western countries16"
19
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1.3.2 Gastro-oesophageal and duodeno-gastro-oesophageal reflux.
It is estimated that 4-9% of patients experience daily heartburn and up to 20%
experience symptoms on a weekly basis (Gallop organisation), and up to almost 30%
experience reflux symptoms at least 6 times during the previous year23. Case control
studies have shown a twofold relative risk of developing adenocarcinoma of the
oesophagus as a result of reflux oesophagitis24. Longstanding severe symptoms have
been shown to be associated with an increased risk of adenocarcinoma with an odds
ratio of 44. The association between reflux and adenocarcinoma of the oesophagus
and gastric cardia is becoming more widely accepted 25;26. The pathogenesis is also
being investigated with an increase in DNA damage seen in patients with reflux
disease27.
A number of studies have shown an increase in DNA damage as a result of reflux of
duodenal fluid suggesting that this may be important in the progression towards
carcinoma. By surgically manipulating the nature of the refluxate in rats, Attwood
and others have demonstated that duodenal refluxate specifically may be important in
the development of adenocarcinoma of the oesophagus 28"30.
1.3.3 Barrett's oesophagus.
Barrett's oesophagus is considered to be a pre-malignant condition with an annual
risk of oesophageal adenocarcinoma of around 0.5%31. It is probably as a result of
chronic reflux that results in the abnormal development of specialised columnar
epithelium in the lower oesophagus. Endoscopic studies demonstrate that, although
less than 1% of the general population has Barrett's oesophagus3 , 5-15% of those
with long-term reflux symptoms will have Barrett's oesophagus of some length33"35.
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1.3.4 Familial and ethnic risk.
There is little evidence to support a strong genetic component to the development of
36* 37
any type of oesophageal cancer ' .
1.4 Pathogenesis and natural history of gastric cancer.
1.4.1 Environmental and dietary agents in gastric cancer.
A number of studies have also shown a role for alcohol and especially tobacco in
30.39 .
gastric cancer development ' . These studies have suggested that the risk with
tobacco relates to the chronicity of exposure rather than the amount smoked per
day40'41. In a meta analysis of the role of tobacco in the development of gastric
cancer, Tredaniel et a\ suggested that worldwide 11% of gastric cancer may be
attributable to tobacco smoking, with a relative risk of around 1.6 over non
smokers42. Heavy alcohol intake has been shown to be correlated with a 6 times
increased risk of gastric cancer41"43.
Environmental agents have also been identified as important in both intestinal and
diffuse-type gastric cancer development44'45. Important among these are the A-nitroso
compounds, which are formed in the stomach from nitrites46. Protective agents have
also been identified, such as vitamin C, which are thought to reduce the A-nitroso
burden47"49. This protective role is supported by the observation that, as with most
cancers, the risk of developing upper GI cancers is lower among those who eat more
fruit and vegetables50"52. Dietary cereal has also been shown to be protective against
• 53 1 •
gastric cardia cancer (and probably oesophageal adenocarcinoma) . Other dietary
risk factors include increased salt5l;52, starch 52and carbohydrate intake54. One study
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found a reduced incidence of intestinal metaplasia in a population given a diet
supplemented with carotene and vitamins A and E55;56.
1.4.2 Familial and ethnic risk in gastric cancer.
In comparison to oesophageal cancer a familial tendency to gastric cancer has been
17
suggested . Zanglieri et al studied the familial occurrence of tumours in 154
individuals with gastric cancer. Among first-degree relatives of the registered
patients there were 30 cases of gastric carcinoma versus 15 cases in a control group
matched for age and sex (Mantel-Haenszel odds ratio [M-H OR] 3.14, p<0.01). This
excess of gastric neoplasms was observed in siblings (17 versus 7, M-H OR 4.33, p<
0.02) but not in parents (13 versus 8, not significant). Overall the risk to first degree
relatives is thought to be in the order of 2 to 3 fold57.
There is also variation in the incidence of gastric cancer among certain ethnic
groups58'59. Migrant studies show that individuals acquire a higher risk of gastric
cancer at an early age60.
1.4.3 The role of H. pylori- the link with gastric cancer
H. pylori has been implicated in the development of gastric cancer, distal to the
cardia; the role ofH. pylori in the development of cardia cancer is unclear.
It is thought that H. pylori infection occurs at an early age 61 and is life-long.
Combining the results of serological studies from 11 developed countries reveals that
between 15 and 54% of the population are infected with H. pylori62. The link
between H. pylori infection and gastric cancer was recognised following several
serological studies which compared stored sera, tested for IgG antibodies to H.
15
pylori, from large cohorts of patients developing gastric cancer and control subjects.
Bacterial seropositivity was significantly more common in those with gastric
adenocarcinoma, with an odds ratio of 2.8 —6.0, suggesting a strong association
between H. pylori exposure and gastric malignancy 63 64 65' 6 although only for non-
cardia and non-junctional tumours65. Further research has shown that differences in
gastric cancer rates are directly related to H. pylori prevalence 67 and studies in the
West and developing countries have shown that prevalence is inversely proportional
to socio-economic status62'68'69.
Although H. pylori infection is prevalent, in up to 50% as stated earlier, less than 1%
of those infected will develop cancer59. This may, in part, be related to the
pathogenicity of the infecting H. pylori with respect to its Cag A expression and also
a feature of the site of infection within the stomach.
Parsonnet et al found that subjects infected with H. pylori who had Cag A antibodies
were 5.8-fold more likely than uninfected subjects to develop gastric cancer. This
was true for both intestinal and diffuse type cancers. By contrast, H. pylori infected
subjects without Cag A antibodies were only slightly, and not significantly, at
increased risk of gastric cancer70.
H. pylori infection causes a chronic active gastritis in virtually all infected
individual71'71"7 . Atrophic gastritis is found in around 80-90% of patients with
gastric cancer and is therefore believed to be aetiologically related to the tumour
development7^. Severe atrophic gastritis accompanying intestinal metaplasia caused
by persistent H. pylori infection is closely related to the development of intestinal
type gastric cancer7 '77. H. pylori may also be involved in the development of diffuse
16
type gastric cancer as shown by epidemiological and histological studies78,79.
Chronic atrophic gastritis is nearly universal in populations at high risk of gastric
cancer80. Approximately 10% of patients with chronic atrophic gastritis will develop
gastric cancer during a 15 year period73'81.
H. pylori is also linked with the development of intestinal metaplasia82;83. As
mentioned earlier, it is known that the intestinal type of gastric cancer is strongly
associated with the presence of intestinal metaplasia and frequently arises within it.
However, only 10% of these patients with this precancerous condition will develop
cancer84. Despite this, Whiting et al advocate considering the follow up of patients
with intestinal metaplasia (of any type) by annual endoscopy suggesting such a
or
strategy may improve the detection of earlier lesions .
I.4.4 The progression from premalignant to malignant change.
It has been proposed by Correa that gastric cancer (intestinal-type) develops through
a sequence of these histological events: normal to diffuse chronic gastritis, often with
mucosal atrophy, to intestinal metaplasia, to dysplasia and finally to invasive
carcinoma86. The relationship between the three types of intestinal metaplasia and
gastric cancer (intestinal type) is at present unclear. It is thought that type III (or
• R1
incomplete intestinal metaplasia) has a greater chance of progression to dysplasia .
As the progression to tumour evolves a dysplastic change occurs. The grading system
of gastric dysplasia is subjective and open to significant interobserver variation
oo
therefore this system is simplified into low and high grade stratification . Clearly
follow up of those patients with significant histology should be considered. Whiting
et al go further and suggest a possible advantage to surveillance of those with
17
atrophic gastritis or intestinal metaplasia and that a multi-centre randomised
controlled trial is warranted85.
1.4.5 Early gastric cancer progression.
A study recently published by Tsukuma et al supports their previous work showing
that the natural history of Early Gastric Cancer (EGC), certainly in the majority of
cases (36/56), is for it to progress to advanced disease; with the median duration of
EGC (before it became advanced) being 37 months89'90. It would seem that early
detection of gastric cancer and early treatment is related to improved outcome91'92.
Many early cancers are believed to go through a life cycle consisting of ulceration,
followed by healing, then re-ulceration. The doubling time for early gastric cancer is
slow1'93, 1.6-9.5 years (577-3462 days) compared with 0.2-0.84 years (69-305 days)
for advanced cancer94.
1.4.6 Genetic markers associated with gastric malignancy.
Genetic factors have been suspected of playing a pivotal role in the etiology of
gastric cancer but no clear inheritance pattern has emerged and environmental
influences remain the focus ofmany current theories of pathogenesis. Current
evidence implicates the non-random involvement of certain chromosomes and
related oncogenes especially Ras and p53. Genes that may predispose to gastric
cancer have not been clearly implicated but some studies indicate a familial
aggregation of gastric cancer95.
Gastric cancer is relatively common worldwide, mainly in its sporadic form, but
familial aggregation of the disease may be seen in approximately 10% of the cases.
This suggests a genetic cause for the cancer in those families that has not been
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identified in most cases. Despite all efforts to determine its genetic basis, a single
syndrome has been characterised, the hereditary diffuse gastric cancer (HDGC),
which is specifically associated with CDH1 (E-cadherin) germline mutations in one
third of the families. The other two thirds and all the gastric cancer families not
fulfilling the HDGC criteria remain without molecular diagnosis96.
1.5 Clinical impact of oesophago-gastric cancer.
1.5.1 Morbidity and mortality
The overall mortality associated with oesophago-gastric cancer in the UK is
substantial, as mentioned earlier (see Table 1.1). However for early gastric cancer
(EGC), defined in 1962 by the Japanese Society ofGastroenterological Endoscopy as
adenocarcinoma confined to the mucosa or submucosa irrespective of lymph node
involvement 97 (which may be present in 10-20%3)(figure 1.4), the 5 year survival is
in excess of 90%98'". Clearly the emphasis should be to identify these patients in
whom a more positive outcome can be expected.
EGC was known to have a favourable outcome as early as 1938 when Saeki reported
patients who had gastric cancer confined to the submucosa had a five year survival in
excess of 90%100. However the reported incidence of EGC in the UK is low. When
UK pathological records were examined the incidence was reported at 3.9%101.
Among resected cases, in Western series, the incidence of EGC was found to be
102
around 10-20% of the resected cancers , whereas the Japanese national records
show that the percentage of early cancers among their resected cases was 40% in
1985 with a gradual increase in detection rates of EGC throughout the country over
the preceding 20 years103. The detection of EGC is increasing in many centres in
Europe, reflecting the increased use of gastroscopy98;l045 jt js however stjjj
significantly less than in Japan103'105. At the Cancer Institute of Tokyo the
percentage ofEGC overtook advanced cancers in 1990 l06.
There are clearly reasons why the detection ofEGC is higher in Japan such as the use
ofmass screening92'107. Other issues include the endoscopic techniques used in Japan
and the differences in the use of acid suppressing medication prior to endoscopy, that
may delay diagnosis, which is not a factor in Japan
In the UK, once cancers have been detected, the results of treatment of oesophago-
gastric cancer are also poor when compared to other parts of Europe. The 5 year
survival rate for gastric cancer in Europe is 21% compared with 12% in
England13'108.When compared to Japan the poor outcome for gastric cancer is
particularly apparent where the 5 year survival is reported as over 60% after curative
resection109'110, compared with the UK 5 year survival of 20-24% 6;111 after curative
resection. Overall the 5-year survival in Japan is around 24%.
1.6 Reasons for discrepancies in outcome
Clearly the discrepancy in outcome is multi-factorial and includes issues regarding:-
1.6.1 Clinical suspicion in primary care and referral for investigation
Recently, this area has been addressed for many cancers including upper GI cancers
(oesophageal, gastric and pancreatic) by the Department of Health with the
development of guidelines to help identify patients who should be referred for urgent
assessment (Referral Guidelines for Suspected Cancer, available from
20
http://www.doh.gov.uk/cancer'). These guidelines identify the following symptoms as
justification for urgent referral
Dysphagia - food sticking on swallowing (any age).




Dyspepsia in a patient aged 55 years or more with at least one of the following
'high-risk' features:
- onset of dyspepsia less than one year ago;
- continuous symptoms since onset.
Dyspepsia combined with at least one of the following known risk factors:
- family history ofUGI cancer in more than two first-degree relatives;
- Barrett's oesophagus;
- pernicious anaemia;
- peptic ulcer surgery over 20 years ago;
- known dysplasia, atrophic gastritis, intestinal metaplasia.
Jaundice.
Upper abdominal mass.
Although the majority of these patients will not have "early" disease, it is hoped that
these guidelines will highlight the cases in primary care that should be referred
urgently, thus reducing the delays observed within primary care.
21
The NICE dyspepsia guideline document has also been released to help GPs manage
dyspepsia including advice as to who should be referred for endoscopy. These are
not designed to improve the outcome of upper GI cancer and increase the threshold
for endoscopy. It is to be seen if these guidelines have a detrimental effect on the
diagnosis of upper GI cancer.
As things stand a number of studies have shown that there are delays in the diagnosis
of oesophago-gastric cancer in the UK112'113. Delays were identified before the
patient saw their general practitioner (GP) (29-80%) and also before referral was
made (23%) and delay in establishing the diagnosis (20-40%). These delays were
attributed to patient's ignorance, general practitioners' reluctance to refer patients and
logistical problems inherent in referral. The median GP stage times were longer than
median hospital stage times for both oesophageal and gastric cancer114. Overall there
is a delay in the diagnosis of around 15% of patients with oesophago-gastric cancer,
with the median delay being around 17 weeks113'115. These studies also indicated that
many patients, up to 50% of those with gastric cancer, were taking some form of
acid-suppressing medication at the time of diagnosis but the effect of this treatment
was unknown.
1.6.2 Patient factors
Clearly the patient's perception of the importance of the dyspeptic symptoms has an
influence on consultation behaviour and management.
For GORD symptoms socio- economic variables do not affect consultation
behaviour, but the patient's age and the burden (number and type) of associated
23
symptoms do" . However for dyspepsia it seems that socio-economic status does
22
affect consultation behaviour; the consultation rate rising from 17% in social class 1
to 29% in social class 4116.
It also appears that consulting behaviour amongst patients with dyspepsia is driven in
part by psychological factors and, in particular, by symptom-related anxiety as well
as by the frequency of dyspepsia, but not primarily by fear of serious disease1 l7J 18.
Anxiety may help sustain health care utilisation once the behaviour has been
established117.
Health promotion initiatives have been looked at to improve the awareness of
dyspepsia amongst the general population in an attempt to mitigate against some of
these traits. One such initiative involved sending letters to patients asking them to
report new dyspeptic symptoms - this strategy increased gastroscopy uptake by
85%119.
1.6.3 Detection at endoscopy
In order to detect a lesion at endoscopy and perform an adequate upper GI
examination, the operator must not only be sufficiently skilled technically to carry
out the procedure but also sufficiently experienced to recognise an abnormality.
1.6.4 Competence
A study of gastroenterology fellows and fourth year surgical residents in the USA
concluded that experience of over 100 procedures was necessary before success was
achieved in 90% of attempts to pass an endoscope through the oesophagus. In this
series the abnormality pick up rate was <85%120. Gjorup el al showed that the ability
to detect a duodenal ulcer known to be present is only 91% 121. Clearly this has
23
implications when trying to detect the relatively subtle mucosal abnormalities of an
EGC.
1.6.5 Chromoendoscopy
In Japan chromoendoscopy (also known as dye-scattering, chromoscopy, dye
staining, vital staining), is widely used to improve the detection of subtle mucosal
changes in both the upper and lower GI tract, such as those ofEGC, early
oesophageal carcinoma and those within Barrett's oesophagus, thus allowing targeted
biopsy (see Figure 1.4). This technique is not routinely utilised in the UK and thus
there is little published UK data regarding its efficacy in improving the endoscopic
detection of suspicious lesions. What is published relates to the use of
chromoendoscopy in the colon for detecting flat adenomas and dysplasia in patients
with colitis 122'123.
The technique utilises the coloured dyes to delineate the surface under scrutiny - be
that oesophageal, gastric or indeed colonic mucosa. Many different stains have been
described for use, singly or in combination, prior to or during endoscopy. These dyes
are classified also by the way that they work. Contrast staining (with indigo carmine,
methylene blue) highlights tissue topography by entering mucosal depressions and
crevices and encircling elevations. Increasingly small or minute (< 5mm) tumours
are being detected and flat "gastritis-like" EGCs are being identified in Japan by the
recognition at endoscopy ofmucosal discolouration or unevenness124. This method of
dye staining is less susceptible to disruption by surface mucus. Absorptive or vital
stains (Lugol's iodine, methylene blue, toluidine blue, cresyl violet) identify specific
epithelial types or cellular constituents by preferential staining. Lugol's solution
reacts with glycogen in the non-keratinised squamous mucosa and produces a dark
24
greenish brown colour. Abnormal mucosa, such as that resulting from inflammation,
dysplasia or carcinoma has a less, if any, glycogen and so is not stained (figure 1.4).
Screening tests in patients with a high risk of oesophageal carcinoma (heavy smokers
and drinkers) have shown a higher diagnostic yield than "routine" endoscopy125. In
Linxian, China, an area with a high rate of oesophageal carcinoma, Dawsey et al
showed that using Lugol's solution improved the sensitivity of detecting high-grade
dysplasia or invasive carcinoma from 62 to 96%. Also, 23% of the cases of severe
dysplasia and 55% of the cases ofmild dysplasia were found after the use of the
dye126. Similar improvement has been demonstrated using methylene blue as a vital
stain. Canto et al demonstrated an improvement in the detection of dysplasia within
Barrett's oesophagus using methylene blue, which stains the abnormal area less
vividly127. Reactive (non-absorbed) stains (Congo red) identify cellular products, for
example by the colour change of a pH indicator (see Tables 1.2, 1.3).
By utilising these dyes in combination a significant improvement can be made in the
detection of gastric cancer. Tatsuta et al reported the endoscopic diagnosis ofEGC
1 OR• I 9Q
by means of an endoscopic Congo red-methylene blue test ' .With routine
examination a correct diagnosis ofminute and flat cancers in the upper stomach was
made in only 27.3% and 25.0% of cases, respectively. However, using the Congo
red-methylene blue test the rates of correct diagnosis were raised significantly to
75.0% and 83.3%, respectively. The test has also been used in the diagnosis of co¬
existing EGC. Using the Congo red-methylene blue method the detection of
simultaneous gastric cancers was increased from 28.3% to 88.9%130. In this test the
Congo red and methylene blue are sprayed onto the surface and after 2-5 minutes
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areas of abnormality are highlighted as "bleached" areas. The mechanism of this
"bleaching" is unknown.
• 131
Generally these dyes are considered non-toxic but care should be taken especially
as the maximum doses are not known, and any excess dye should be aspirated.
Specifically methylene blue used for chromoendoscopy has virtually no side effects
1T9 • •
although it may cause discolouration of the urine and stool, about which the
patient should be warned133. Certain dyes must be used with caution - Lugol's
solution can cause nausea and heartburn in higher concentrations and due to its
iodine content should not be used in those with a known iodine allergy or in those
with hyperthyroidism; toluidine blue can cause nausea, vomiting and restlessness,
agranulocytosis and methaemoglobinaemia, at higher concentrations, and in the
clinical setting has been surpassed by Lugol's solution133. Occasionally (intravenous)
indigocarmine has given rise to cardiovascular instability, probably related to
stimulation of alpha receptors134 and (intravenous) methylene blue has been
• 1TS
associated with haemolytic anaemia in infants .
There is little data on the effect of chromoendoscopy on the subsequent diagnosis of
H. pylori using a rapid urease test (Clo™) although methylene blue is thought not to
• *1
affect this test or histopathological examination for the diagnosis ofH. pylori .
I.6.6 Biopsy techniques
Once a lesion has been detected, endoscopy allows samples of the suspect lesions to
be collected for pathological examination, which is a distinct advantage over other
methods of diagnosis, in particular, radiological methods such as the barium meal.
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When considering the detection of EGC, endoscopy has a clear advantage over
barium studies101'137.
It has been shown that the accuracy of sampling, by biopsy or fine needle aspiration
and brushing, for the diagnosis of oesophageal cancer can approach 100%138.
Endoscopic diagnosis of gastric cancer appears to offer similar levels of accuracy,
around 98%l39. It is known, however, that several biopsies are often needed to
confirm the diagnosis of cancer. The more biopsies that are taken increases the
diagnostic yield, such that 100% positive yield was achieved with 6 oesophageal
biopsies140. Graham et al showed that 1 biopsy was sufficient to make the diagnosis
in 70% of gastric cancers and 93% of oesophageal cancers but 7 biopsies was the
optimum to ensure diagnoses were not missed141.
1.6.7 Antisecretory drug therapy
A further factor, which may influence the detection of cancers at endoscopy, is the
use of antisecretory drug therapy.
H2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) account for
approximately 15% of primary care prescribing costs in the UK and in the period
1991-95 the number of new prescriptions rose by 174.5%. It would appear that there
was also an increase in prescribing for unlicensed indications such as non-ulcer
dyspepsia and non-specific abdominal pain142'143.
There are two issues relevant to antisecretory drug use and the delay in the diagnosis
of cancer. Firstly, rapid control of dyspepsia may lead patients and/or their GP to
underestimate the importance or significance of the symptoms so referral for
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investigation is delayed. Secondly, these treatments may result in lesions healing
such that they are missed completely or mis-diagnosed as benign at endoscopy.
Antisecretory drugs have certainly been shown to reduce the occurrence ofmucosal
inflammation at endoscopy. The odds ratio of not having mucosal inflammation
when ulcer healing drugs were taken within 2 weeks of gastroscopy was 3.1 (95% CI
1.3-7.1 p<0.01) and the odds ratio when these drugs were taken 2-4 weeks before
was 2.0 (95% CI 1.0-3.9 p<0.04). Clearly the use of these medications reduces
diagnostic yield144. Antisecretory medication has also been implicated in the mis¬
diagnosis of lesions at endoscopy. In a retrospective study looking at the effect of
antisecretory medication on the diagnosis, and earlier mis-diagnosis, of oesophago-
gastric cancer, 133 patients were identified over a 3-year period. Only one of the 54
patients (1.9%) on no treatment, or antacid alone, was erroneously diagnosed with
benign disease at an earlier endoscopy whereas 22 of 62 (35.5%) of those treated
were mis-diagnosed ll5. Thus acid-suppressing medication is implicated in the mis¬
diagnosis of the malignancy at the first endoscopy: the diagnosis may have been
masked in some patients whose lesions appeared benign (particularly ulcers, with
confirmatory biopsy results), and who continued on acid suppression after the
endoscopy. Only when the malignancy became manifest were some patients
discovered to have had an earlier endoscopy which demonstrated minor
abnormalities or normal results. There are other reports ofH2RA and PPI "masking"
gastric cancers at endoscopy1451146. Presumably these powerful acid-suppressing
medication allowed healing to occur with re-epithelialisation providing a covering of
normal mucosa over the underlying malignancy, or there is sufficient healing to
make a lesion appear less "suspicious" to the endoscopist (see figure 1.5). Associated
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with this is a resulting delay in the diagnosis of patients with oesophago-gastric
cancer if they have been taking treatment1 5,1 1. Clearly associated with the healing
of the lesions may well be a resolution or at least a modification of the symptom
complex as a result of treatment. Certainly there are reports of such, with cimetidine
resulting in healing of ulcers and resolution of symptoms143 and similar with PPIs
apparently causing resolution of the symptoms associated with malignancy147.
1.6.8 Availability of and access to endoscopy
Current estimates suggest that the provision of open access in Britain has risen from
about 50% in 1990 to around 75% in 1994, with two thirds of those not offering open
access then hoping to do so in the near future148'149. GPs appear to use open-access
endoscopy services effectively and this can avoid a large number of unnecessary
outpatient clinic visits150"152. A Danish randomised study which compared prompt
endoscopy for patients with dyspepsia (average age 44 years) with attempted
symptom control with an fh receptor antagonist found that prompt endoscopy was
associated with reduced prescribing, further consultation and days lost from work in
patients with dyspepsia133. The proportion of patients with malignancies is generally
as high among patients referred by GPs as among patients referred by specialists.
Overall 1-2% of patients referred for endoscopy were likely to have cancer151'154'155.
Although several studies suggest that rapid access to endoscopy could be associated
with improved survival, there is as yet no evidence that demonstrates this
unequivocally. Prompt access to endoscopy tends to yield a higher proportion of
early (treatable) cancers, but there has been no comparative study demonstrating that
this affects long-term survival rates151'154'156'157.
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Although diagnostic endoscopy is not risk-free, most adverse effects are mild and
transient, such as sore throat and a feeling of bloatedness. A 36 hospital audit
demonstrated that the morbidity rate associated with gastroscopy is around 1 in 200,
the perforation rate is around 1 in 2,000, and the overall death-rate around 1 in
10,000158.
1.6.9 Treatment
Essential to successful treatment of oesophago-gastric cancer is accurate staging.
This is multi-modality but involves at least spiral CT scanning and often endoscopic
ultrasound; in selected cases ultrasound, MRI or laparoscopy may be essential to
stage accurately. Following staging all cases should be discussed in a multi-
disciplinary meeting to formulate the best management plan which is often multi¬
modal. In depth discussion of the treatment of oesophago-gastric cancer is beyond
the scope of this thesis.
Suffice to say, it would appear that the crucial factor, if the results of treatment in
Britain and the West are to improve, is earlier diagnosis.
Improving endoscopic practice is one way to improve the detection of early disease
but other areas that contribute to delayed or late diagnosis also need to be identified
and addressed.
Aims
This thesis aims to clarify and resolve these issues of late diagnosis of oesophago-
gastric adenocarcinoma in the UK. It has the following parts: -
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• To quantify the delays in diagnosis of oesophago-gastric adenocarcinoma and
evaluate the effect of antisecretory drug therapy on the delays and outcome
• To identity the effect of strategies to facilitate referral.
• To identify how many cancers are missed at endoscopy.
• To investigate the use of chromoendoscopy.
• To investigate the endoscopist's evaluation of histopathology from the
appearance of ulcer disease.
Each of these topics is dealt with in a separate chapter. Where necessary ethics
committee approval was obtained.
Figure 1.1 Oesophageal adenocarcinoma
Figure 1.2 (a) Gastric cardia adenocarcinoma
Figure 1.2 (b) Distal gastric adenocarcinoma
Figure 1.3 (a) Ulcerated gastric adenocarcinoma
Figure 1.3 (b) Ulcerated gastric adenocarcinoma showing endoscopic view and
resected specimen.
Figure 1.3 (c) "Mass-like" gastric adenocarcinoma
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Figure 1.4 (a). Early oesophageal cancer (a) without dye (b) with iodine.
Figure 1.4 (b). Early gastric cancer (a) before dye spray (b) after dye spray.
Figure 1.5. Healed gastric adenocarcinoma (a) without dye (b) with
methylene blue.
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Cancer site Incidence: rate per One-year Five-year Deaths, Death rate per
100,000 survival survival England & 100,000,
rate, rate, Wales, England and
England England 1997 Wales
Men Women Men Women
Oesophagus 14.0 9.2 27% 9% 5,855 13.6 8.4
Stomach 24.3 13.8 28% 12% 6,613 15.1 9.5
Table 1.1. Oesophageal and gastric cancer: incidence, survival and death
rates1:l3;l59.
Contrast staining Emphasises depressions and protuberances of uneven mucosal
surfaces by making use of dye solution pooling. Useful for
morphological diagnosis.
Dyes: indigo carmine, Evan's blue, brilliant blue, methylene blue
Vital staining For observing stain in biological tissues caused by infiltration,
absorption and direct staining by dye solution.
Dyes: methylene blue, toluidine blue, azure A
Reaction staining Utilises the specific reaction of the dye solution under specific
circumstances.
Dyes: Congo red, crystal violet, Lugol's iodine, phenol red
Fluorescent staining Utilises fluorescence of orally or intravenously prescribed dye
solution.
Dyes: fluorescein, acridine orange
Intravascular staining Use of intravascular dye to delineate vasculature
Dyes: indigocyanine green
Combined method Combination of above methods.
Table 1.2. Classification of endoscopic dye methods (Japanese
Gastroenterological Endoscopy Society)
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Method Dye Colour Concentration
Contrast staining Indigo carmine Blue 0.1-0.5%
Evan's blue Greenish blue 0.1-0.2%
Brilliant blue Blue 0.5-1.0%
Vital staining Methylene blue Blue 0.2-1.0%
Toluidine blue Purplish blue 0.2-1.0%
Azure A Purplish blue 0.2
Reaction staining Congo red pH 3 purplish blue 0.3-0.5%
pH5 red
Crystal violet pH dependent 0.05%
Lugol's iodine Reddish brown 1-3%
Phenol red From yellow to red 0.5% (use with urea)
Table 1.3. Concentration of dye solutions.,33;160;161
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Chapter 2 Delays in the diagnosis of oesophago-gastric
cancer
2.1 Introduction
As stated earlier, for more than half a century the overall incidence and mortality
rates of gastric cancer have been slowly declining 4 although adenocarcinoma of the
5 7
gastric cardia is becoming more common " . The incidence of adenocarcinoma of the
oesophagus is also increasing; this has been attributed to the increasing prevalence of
gastro-oesophageal reflux9. Adenocarcinoma of the oesophagus is now the
commonest form of oesophageal cancer9"1'.
In the United Kingdom there are often delays in the diagnosis of oesophago-gastric
cancer 1l2;113 for reasons that are unclear but that are likely to be multifactorial.
Patients may delay seeing a doctor and referral to hospital may be deferred by a
previous history of dyspepsia 162 or absence of alarm symptoms163. Many other
factors are likely to influence the process leading to delays in obtaining endoscopy
and thus establishing a diagnosis but where possible these should be addressed
through health promotion and GP education. As mentioned one health promotion
initiative looked at improving the awareness of dyspepsia amongst the general
population by sending letters to patients asking them to report new dyspeptic
symptoms - this strategy increased gastroscopy uptake by 85%'19. Quality
improvement initiatives in health services rely upon the effective introduction of
clinical practice guidelines. However, even well constructed guidelines have little
effect unless supported by dissemination and implementation strategies. One study
looking at the effectiveness of supporting guidelines with seminars suggested that
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educational outreach may be more effective than passive guideline dissemination in
changing clinical behaviour164.
In addition, and more specifically, the empirical use of antisecretory drugs prior to
diagnosis, particularly proton pump inhibitors (PPIs) can contribute to the delay
through the modification of symptoms and the potential healing of early malignant
ulcers147. Also, dyspepsia management guidelines increasingly advocate empirical
therapy for H. pylori negative patients under 55 years without alarm symptoms ;
thus people who have previously received antisecretory drug therapy are likely to
receive further prescriptions when symptoms recur.
Despite this trend towards empirical therapy there is no data available with regards




The aim of this study was to identify the delays in diagnosis of oesophago-gastric
adenocarcinoma by focusing on the patterns of presentation. The effect ofprior
antisecretory drug therapy on the time to a definitive diagnosis and the effect on
symptoms, tumour stage and outcome were also studied.
2.3 Patients and Methods
The study design was a survey of the records of all patients with an established
diagnosis of primary oesophageal or gastric adenocarcinoma over the ten-year period
April 1991-April 2001, in a fixed population base.
The study was based in the South Tees health district of Teesside, a mixed industrial
and rural area with a catchment population of approximately 300,000. Due to the
centralisation of gastroenterology services it is estimated that over 95% of all
patients referred with gastrointestinal problems are seen at one hospital, the James
Cook University Hospital (formerly South Cleveland). This enabled central access
to patient records, and endoscopy and pathology reports. Both primary and secondary
care records were accessed.
To meet the inclusion criteria patients had to have a definitive cancer diagnosis
established within the population area, for the first time, in the ten years to April
2001.
Patients were initially identified from the computerised pathology database. The list
obtained was cross-referenced with the regional cancer registry (Northern and
Yorkshire Cancer Registry and Information Service) and the hospital's own cancer
records to ensure completeness and accuracy of the patient cohort. The identified
patients' primary care records were reviewed at their general practices or, where the
patients were dead, retrieved from the central registry of Tees and North Yorkshire
Health Authorities. These were reviewed to record demographic characteristics and
to detail the diagnostic pathway leading to the definitive diagnosis and eventual
outcomes. These details included the timings of the onset of symptoms, first GP
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consultation with new onset symptoms and the timings of referral and investigations.
Details about the prescribing of antisecretory drugs prior to investigation were also
recorded and the hospital records reviewed for endoscopy findings, including the
endoscopist, number of biopsies taken, tumour stage at diagnosis and long-term
outcome.
2.3.1 Statistics
Data handling and analysis was performed using the Epi Info™ epidemiological
database and statistical analysis package (US Department of Health and Human
Services Centre for Disease Control, Atlanta, Georgia). The accuracy of data entry
was optimised by using double data entry and cross checking. Data were analysed
using parametric methods for normally distributed continuous data (t test, ANOVA)
and non-parametric methods (x , Kruskal Wallis) for categorical data and non-
normally distributed continuous data. Results were considered to be statistically
significant with p values <0.05 (95% confidence limits).
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2.4 Results
A total of 747 patients with adenocarcinoma (ACA) (squamous carcinomas
excluded) were identified of whom 685 (92%) were included in the study. Medical
records for 15 patients (2%) were missing and 47 patients (6%) were excluded
because they were found not to have had a primary gastric or oesophageal
adenocarcinoma or had the diagnosis made prior to the study period. Two patients
had all investigations and the diagnosis made outside of the population area and four
had incidental post mortem findings of oesophago-gastric ACA (not the cause of
death).
Table 2.1 and Figure 2.1 detail patient numbers.
Table 2.1. Demographics for all upper GI adenocarcinomas with oesophageal and
gastric subsets.
Figure 2.2. Details of study cohort.
Figure 2.3 Age and sex distribution at diagnosis.
2.4.1 Referral patterns
The mean time from first symptoms, as recorded in the notes from the patients'
history, to diagnosis, was 30 weeks (range 1-428) (table 2.1). Compared to patients
with gastric adenocarcinoma those with oesophageal adenocarcinoma took longer to
present to their GP (mean 16.4 weeks v 12.2) (p=0.003) and longer to be seen in
secondary care once referred (p=0.03). All the other time periods (time to be
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referred, time to definitive diagnosis) showed no statistically significant differences.
The mean and median time durations during which the patient remained under
primary care management only was double the hospital phase times, for both
oesophageal and gastric cancer (22.0 (8) and 19.4 (6) v 10.0 (3) and 9.4 (3) weeks
respectively) (p<0.0001). There were no significant differences between the time
periods the patient remained in primary care alone or in hospital management for
either oesophageal or gastric cancer.
Details are shown in table 2.1.
2.4.2 Symptoms
Figure 2.3 shows the symptoms as recorded in the GP and hospital notes at the
various stages in the diagnostic process. Initially only 50% of patients had alarm
symptoms (i.e. anaemia/dysphagia/weight loss/vomiting). By the time of referral this
had risen to 71% and at diagnosis to 78%.
2.4.3 Empirical Treatment
Overall, of the 685 patients with adenocarcinoma 47.7% had antisecretory drugs
treatment between the onset of symptoms and diagnosis. In 66.8% this was initiated
at the first GP visit. Patients with oesophageal adenocarcinoma were more likely than
patients with gastric adenocarcinoma to be taking antisecretory drugs prior to their
first GP consultation with new onset symptoms (13.6% v 6.2%) (p=0.002). Patients
were predominantly prescribed PPIs although 33.9% were on a H2RA beforehand.
There was no significant difference between males and females in relation to rates of
antisecretory drugs prescribing at any stage. Details are shown in Table 2.1.
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2.4.3.1 Antisecretory drug prescribing and time to diagnosis of cancer
An increase in the time to diagnosis was associated with the use of antisecretory
drugs at all stages (Table 2.1). The time interval before referral from primary care to
hospital was significantly longer in those prescribed antisecretory drugs compared
with those who were not prescribed these. This was irrespective of the presenting
symptoms except for those presenting with haematemesis/ melaena. For those treated
with antisecretory drugs prior to gastroscopy the mean time from their first GP visit
with new onset symptoms to diagnosis was increased by 17.6 weeks (p<0.001).
2.4.3.2 Effect of AST on symptoms
The number of patients with alarm symptoms at each stage of the diagnostic
pathway, in relation to whether or not they were prescribed antisecretory drugs is
shown in Figure 2.3. In total 339 (49.5%) of patients had benign symptoms at their
first GP consultation; of these 175 (51.6%) were given antisecretory drugs. For
patients with alarm symptoms 20.2% were prescribed antisecretory drugs. Thus
patients with more benign sounding symptoms were more likely to have been
prescribed antisecretory drugs (p<0.0001).
Patients with benign symptoms prescribed antisecretory drugs (n=175) were referred
later than patients with benign symptoms not given antisecretory drugs (n=164)
(mean 16.4 v 5.54 weeks, median 8 v 1 weeks, p<0.0001). Similarly, patients with
alarm symptoms were referred later if antisecretory drugs had been prescribed (5.6 v
1.8 weeks, median 1 v 0, p=0.0008). Thus the use of antisecretory drugs was
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associated with a longer time to referral. During this period more patients developed
alarm symptoms. However, 98.6% of patients with alarm symptoms at the first GP
consultation and who were prescribed antisecretory drugs still had alarm symptoms
by the time of hospital consultation. This suggests that the use of antisecretory drugs
did not change alarm symptoms to benign sounding symptoms.
2.4.3.3 Effect of antisecretory drug therapy on tumour stage at diagnosis
Staging data using the TNM classification 165 (appendix II) was available for 477
patients (70% of total). Of these 287 underwent surgery. Treatment with
antisecretory drugs was not associated with the tumour stage at diagnosis for either
oesophageal or gastric adenocarcinoma (p=0.49 and p=0.31 respectively) as shown
in Table 2.1.
2.4.3.4 Effect of antisecretory drug therapy on survival
The effects of empirical antisecretory drugs on survival (Kaplan-Meier) following
diagnosis are shown for both oesophageal adenocarcinoma and gastric
adenocarcinoma in Figure 2.3 (a)-(d). No significant differences were observed
between the two groups except for gastric adenocarcinoma where patients with stage
Ilia disease had a worse prognosis with prior empirical antisecretory drugs.
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2.5 Discussion
PPIs are now the drugs of choice for treating symptomatic reflux and their efficacy
means that increased prescribing of these powerful acid suppressants is a modern
phenomenon seen in many western countries143'166. Concern about these drugs
masking cancer or delaying diagnosis 1 l5;l47;162;162 is therefore important if the net
effect is to worsen prognosis.
Symptoms are the major influence on the timing and presentation of patients to their
General Practitioner and subsequent referral for investigation. The vast majority of
dyspeptic patients in the 'at risk' age group will have benign disease, even if some of
• 167' 168their symptoms are 'worrying', as symptoms are a poor predictor of pathology ' .
Some patients are also very elderly and would potentially not be suitable for surgery
even if diagnosed early. However the mean age was 70.3 years at diagnosis and we
can find no evidence that age per se delayed referral.
A limitation of this study is its retrospective nature and that only those with cancer
were studied rather than the dyspeptic population as a whole. However, the fact that
patients with oesophageal adenocarcinoma took longer to present to their GP
suggested that they were not concerned by their symptoms until relatively later.
These patients were also more likely to have been on antisecretory drugs previously,
compared to those with gastric adenocarcinoma.
This study confirms previous work showing that patients given antisecretory drugs
endure a delay to a definitive morphological diagnosis. Patients given antisecretory
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drugs on their first visit to the GP had a longer time to diagnosis at all stages of the
process but the longest delay occurred because patients previously prescribed
antisecretory drugs did not seek a further medical opinion and when they did, the GP
was likely to restart the antisecretory drugs rather than refer for investigation.
Patients with worrying symptoms received antisecretory drugs less frequently and
were referred quickly compared to those with more dyspeptic symptoms. In many
cases the delay was many months during which time it might be assumed that the
tumour would progress significantly and worsen both the stage of the disease at
diagnosis and long-term survival. The results indicate this did not happen. Those
patients with early stage disease (early gastric cancer or stage I disease) had the
longest period on treatment but were still 'early' when eventually diagnosed.
The reasons for this are probably explained by the natural history of upper
gastrointestinal adenocarcinoma. In the oesophagus the disease spreads relatively
QO
early and even those patients referred quickly are likely to have disease that has
infiltrated the lymphatics, making curative resection less likely. Thus delays resulting
from prior antisecretory drugs are unlikely to affect prognosis. In relation to stomach
cancer, patients with early disease were more likely to have benign symptoms and
more likely to have been prescribed antisecretory drugs. Tumour-doubling time is
long in early stage disease 93>94>169 making a delay less critical in terms of tumour
stage at diagnosis. Patients with alarm symptoms have more advanced disease 6
associated with a rapid tumour doubling time94. In this study patients with alarm
symptoms were less likely to receive antisecretory drugs and were referred more
quickly. Thus those patients presenting with mucosal disease and benign sounding
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symptoms in primary care still had mucosal disease when diagnosed at gastroscopy
despite many months' delay.
In conclusion, this study confirmed that empirical antisecretory drug therapy was
associated with a significant delay in arriving at the definitive diagnosis of cancer but
revealed the new information that this did not affect the tumour stage at diagnosis.
Also the long-term outcomes were identical in those who had been prescribed
antisecretory drugs prior to diagnosis and those who had not. Withholding
antisecretory drugs prior to investigation may accelerate a definitive diagnosis but is
not likely to affect the eventual outcome. We cannot recommend routinely treating
'at risk' patients with antisecretory drugs prior to gastroscopy, as patients will still
perceive this as a delay. However this data does support the concept that such a delay
has little significance, as outcome is poor in both groups.
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All Oesophageal Gastric
Total number 685 198 487
Male 451 143 308
Female 234 55 179
Mean age at diagnosis
(range) in years
70.3 (28-94) 69.4 (41-94) 70.7 (28-92)
% under 45 years at
diagnosis
2.6 (n=18) 1.5 (n=3) 3.1 (n=15)
% under 55 years at
diagnosis
8.9 (n=61) 10.1 (n=20) 8.4 (n=41)
Mean time to diagnosis
in weeks (median, range) 29.7(14, 1-428) 32.0(15, 1-428) 28.8(13, 1-415)
Mean primary care stage
time in weeks (median,
range)
20.2 (7, 1-423) 22.0(8, 1-423) 19.4 (6, 1-408)
Mean hospital stage time
in weeks (median, range) 9.6 (3, 1-165) 10.0(3, 1-164) 9.4 (3, 1-165)
% patients prescribed
















Mean time to diagnosis













p <0.0001 p <0.0001 p <0.0001
Mean stage times in
weeks (median) +AST, -AST +AST, -AST +AST, -AST
1st symptom to 13.4(4) 58.6(6), 9.3(4) 16.4(4)59.4(4), 9.6(4) 12.1(3)57.8(12), 9.1(2)
1st GP visit p<0.0001 p=0.04 p<0.0001
1st GP visit to 6.8(1) 13.3(5), 3.2(0) 5.6(1) 9.7(3), 3.2(0) 7.3 (1) 14.9 (6), 3.2 (0)
referral p<0.0001 p<0.0001 p<0.0001
Referral to Is' 2.7(2) 3.0(2), 2.5(1) 2.8(2) 2.9(2), 2.8(2) 2.6(2) 3.1 (2), 2.3(1)
hospital contact p=0.003 vo©IIc. p=0.002
1st hospital 6.9(0) 12.7(1), 2.5(0) 7.2(0) 14.2 (54), 1.5(0) 6.8(0) 12.1 (1), 2.9(0)
contact to p<0.0001 p=0.0005 p<0.0001
diagnosis
TMN stage at +AST, -AST +AST, -AST
diagnosis
- 2 1, 1 3 3, 0
0 (Tis) - 10 7, 3 45 20, 25
I - 19 11, 8 43 23, 20
II - 37 15, 22 107 51, 56
III - 39 19, 20 172 76, 96
IV 91 42, 49 117 58, 59
Stage unknown





25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85- 90-
29 34 39 44 49 54 59 64 69 74 79 84 89 94
Age group
□ FEMALES a MALES
Figure 2.1 Age distribution at diagnosis.
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Diagnosis outside catchment area
Incidental post mortem diagnosis
FIRST SYMPTOMS - ADENOCARCINOMA OESOPHAGUS
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
OESOPHAGUS
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
OESOPHAGUS




□ EPIGASTRIC PAIN (BENIGN)
□ BLEEDERS
□ ANAEMIA/DYSPHAGIA/WEIGHT LOSS
Figure 2.3 Symptoms as recorded in the GP notes at the various
stages of the diagnostic pathway with and without the patient taking
AST.
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FIRST SYMPTOMS - ADENOCARCINOMA OESOPHAGUS
ON AST
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
OESOPHAGUS ON AST
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
OESOPHAGUS ON AST
5%
SYMPTOMS AT DIAGNOSIS - ADENOCARCINOMA
OESOPHAGUS ON AST
□ DYSPEPSIA/HEARTBURN/REFLUX
□ EPIGASTRIC PAIN (BENIGN)
□ BLEEDERS
□ ANAEMIA/DYSPHAGIA/WEIGHT LOSS
FIRST SYMPTOMS - ADENOCARCINOMA OESOPHAGUS
NOT ON AST
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
OESOPHAGUS NOT ON AST
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
OESOPHAGUS NOT ON AST
7% 2%
SYMPTOMS AT DIAGNOSIS - ADENOCARCINOMA




□ EPIGASTRIC PAIN (BENIGN)
□ BLEEDERS
□ ANAEMIA/DYSPHAGIA/WEIGHT LOSS
FIRST SYMPTOMS - ADENOCARCINOMA STOMACH
28%
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
STOMACH
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
STOMACH
8%




□ EPIGASTRIC PAIN (BENIGN)
□ BLEEDERS
□ ANAEMIA/DYSPHAGIA/WEIGHT LOSS
FIRST SYMPTOMS - ADENOCARCINOMA STOMACH ON
AST
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
STOMACH ON AST
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
STOMACH ON AST
14%




□ EPIGASTRIC PAIN (BENIGN)
□ BLEEDERS
□ ANAEMIA/DYSPHAGIA/WEIGHT LOSS
FIRST SYMPTOMS - ADENOCARCINOMA STOMACH NOT
ON AST
SYMPTOMS AT 1ST GP CONSULT - ADENOCARCINOMA
STOMACH NOT ON AST
SYMPTOMS AT REFERRAL - ADENOCARCINOMA
STOMACH NOT ON AST
6%
0
SYMPTOMS AT DIAGNOSIS - ADENOCARCINOMA
STOMACH NOT ON AST
□ DYSPEPSIA/HEARTBURN/REFLUX
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Figure 2.4 Kaplan Meier Survival curve for oesophageal carcinoma and the
effect of antisecretory drug therapy (AST)
♦ HAD AST ■ NO AST
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Survival (weeks)
Figure 2.5 Kaplan Meier Survival curve for gastric carcinoma and the effect
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Figure 2.6 (a). Kaplan Meier Survival Curves for oesophageal





























Figure 2.6 (b). Kaplan Meier Survival Curves for oesophageal
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Figure 2.6 (c). Kaplan Meier Survival Curves for gastric
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Figure 2.6 (d). Kaplan Meier Survival Curves for gastric
adenocarcinoma and the effect of anti-secretory drug therapy
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Chapter 3. Effect of strategies to facilitate referral
3.1 Introduction
In the National Cancer Plan 170 the UK government introduced Urgent Cancer
Referral Guidelines (the 'two-week rule') to ensure that everyone with suspected
cancer would be referred to a specialist by their general practitioner and seen within
two weeks of the referral date. Clearly this was intended to reduce some of the delays
highlighted in Chapter 2. From the outset however there were doubts that these
guidelines would actually improve the outcome of patients diagnosed with upper GI
cancer given the poor correlation of symptoms with diagnosis and the emphasis on
"alarm" symptoms as the trigger for endoscopy.
Although the onus may seem to be solely on the secondary care sector, there are
undoubtedly issues for primary care. This is particularly evident in the area ofUGI
symptomatology where annually large numbers of dyspeptic patients are seen, few of
85'171 172
whom will have malignancy ' ' .
In the past General Practitioners have been reluctant to use 'open access' gastroscopy
1 f\')
for patients with suspected cancer and targeted two-week rule referrals have the
potential to overwhelm individual clinicians and increase referral times for cancer
patients with less obvious symptoms173. This strategy may therefore be detrimental.
In June 2000 the guidelines were issued to General Practitioners highlighting the
symptom complexes experienced by patients with UGI malignancy but the evidence
base is acknowledged to be poor174'175. The cancer detection rate from the new policy
has been low l71;172 and the majority of patients with 'two-week' criteria will not have
upper GI malignancy176
We were interested to see how far we had been historically from this ideal during the
last ten years and how many of our patients with known UGI malignancy would have
fulfilled the "2-week rule" had the same criteria been in place.
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3.2 Aims
The aim of this study was to examine referral practice utilising the "two-week"
criteria for all patients diagnosed as having UGI AC during the 10-year period April
1991-April 2001 to see whether lessons could be learned from previous referral
practices.
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3.3 Patients and methods
The previously identified cohort of patients with oesophago-gastric adenocarcinoma
was studied. Primary care, hospital and pathology records were reviewed with
respect to the Urgent Cancer Referral Guidelines and the data analysed using Epi
Info™.
3.3.1 Statistics
Data was analysed using parametric methods for normally distributed continuous
data (t test, ANOVA) and non-parametric methods (% Kruskal Wallis) for
categorical data and non-normally distributed continuous data. Results were
considered to be statistically significant with p values <0.05 (95% confidence limits)
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3.4 Results
Of the study cohort a total of 494 patients (72.1%) fulfilled the major two-week rule
criteria in terms of symptoms at the initial consultation with the General Practitioner
(table 3.1) comprising 338 (69.1%) males, mean age 69.3 years (range 40-92). Males
were more likely to fulfil the two-week rule criteria (p<0.03) and females were
significantly older (mean 74.3 years, range 35-94) p<0.001.
3.4.1 Individual symptom complexes
The largest group of patients fulfilling the two-week rule criteria were those aged 55
years and over with dyspepsia or epigastric pain less than 1 year with continuous
symptoms since onset (n=244). The mean time from first symptoms to seeing the GP
was 6.6 weeks and 68 were referred immediately to secondary care (27.9%)
increasing to 119 (48.8%) by four weeks. The second largest group comprised
patients with dysphagia (n=l 15) ofwhom 80 (69.6%) had this as the main presenting
symptom. The duration of dysphagia varied from within 1-26 weeks with a mean
time of 5.1 weeks before consulting the GP. There were 49 patients with dyspepsia
or epigastric pain with weight loss at their first consultation of whom 39 (79.6%)
recalled simple dyspepsia or epigastric pain (without weight loss) as the first
presenting symptom (mean duration 24.8 weeks, range 1-208). Dyspepsia or
epigastric pain associated with anaemia accounted for 14 (3.8%) patients (mean time
to initial consultation 39.0 weeks range 1-208). There were 11 patients (3%) with
dyspepsia or epigastric pain associated vomiting and nine patients (2.4%) with an
epigastric mass. All 29 patients presenting with acute GI bleeding had a short history
of dyspepsia or epigastric pain and 25 (86.2%) were acute admissions. The minimal
times to referral (mean 0.2 weeks) and being seen at the hospital (0.6 weeks) reflect
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the acute nature of their symptoms. In the whole group (685 patients) referral to
secondary care within four weeks varied from 41.2% to 100%. The proportion of
patients seen within two weeks varied from 39.9% to 89.7% and was lowest in the
most common symptom group (39.3%). At four weeks all patients with an epigastric
mass had been seen but only 66.8% of patients over the age of 55 years and a short
history of dyspepsia had been seen.
3.4.2 Correlation between GP priority and Specialist priority
The time taken for the GP to refer a patient following initial consultation would have
been largely unknown to the specialist receiving the referral. However the priority
placed on the referral by the GP (in terms of the number referred by four weeks) was
closely matched by the percentage of patients seen with a particular symptom
complex within four weeks (Spearman-rank correlation coefficient = 0.79 p< 0.05).
3.4.3 Patients for whom the two-week rule did not apply
There were 191 patients (27.9%) who did not fit the major urgent referral criteria for
suspected UGI malignancy at the first consultation in primary care (table 3.2), of
whom 113 (59.2%) were males, mean age 66.6 years (range 28-93). Females were
significantly older (mean age 72.0 years, range 37-88 ;p<0.001). Within the group
there were no significant differences between the sexes in the mean time to referral
or being seen by secondary care. The mean time to referral was 7.1 weeks (range
within 1-137 weeks). Almost half (49.2%) were seen within two weeks and 69.6%
by four weeks. The majority of these patients subsequently developed symptoms
fitting referral criteria. There were 53 patients (16.8%) with weight loss but no upper
GI symptoms at initial consultation, although 34 patients subsequently developed
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these. Patients without UGI symptoms but with anaemia accounted for 31 patients
(9.8%). There were 14 emergency admissions with severe anaemia but no GI
symptoms, seven patients with sudden collapse, four patients with chest pain and
seven patients with ill-defined symptoms such as fatigue and lethargy.
31 patients aged 55 years or under presented with benign symptoms (dyspepsia or
epigastric pain alone). Almost all (93.5%) had symptoms for less than one year and
45.2% had symptoms for less than one month prior to consulting their GP. Time to
referral ranged from 1-137 weeks (mean 17.7 weeks) but only 6 patients (19.4%) had
worrying symptoms at the time of referral. Only 16 patients over 55 years of age had
a history longer than 12 months and the referral time was also long (26.9 weeks). At
the time of referral 5 patients (31.3%) had developed worrying symptoms.
3.4.4 Differences between the two groups
Females were significantly older than males in both groups and patients under the
age of 55 were more likely to have benign symptoms than patients over this age




The aim of this study was to assess the robustness of the current referral guidelines,
viewed from the primary care perspective. At present the evidence base relating to
symptoms comes from hospital based studies based on symptoms present in patients
found to have malignancy on gastroscopy174;175. The precise percentage of patients
presenting with alarm symptoms in primary care is unknown, although recently a
figure of 10% has been reported in patients presenting with dyspepsia177, and yet the
current guidelines are primarily aimed at general practitioners. It therefore seemed
appropriate to examine symptoms before the patient was referred to hospital. In
addition we wanted to assess the past performance of both primary and secondary
care, in terms of the referral pathway, for patients subsequently diagnosed with UGI
ACA.
The results indicate that there is good correlation between the priority General
Practitioners' place on symptoms, as judged by speed of referral and the specialist's
priority as determined by the time to be seen. Despite this agreement, before the
inception of the 'two-week rule', specialists were able to see only 46.4% of patients
with alarm symptoms within two weeks. In a system with a finite number of
endoscopy sessions, diagnosis of patients without alarm symptoms is likely to be
delayed173. In this series the largest group not fulfilling the new upper GI urgent
referral guidelines were patients with weight loss but no upper GI symptoms (n=53)
or patients below 55 years of age with benign symptoms (n=31). Only a third of
patients in the latter group were referred by two weeks, one third ofwhom, were seen
by two weeks. At present lowering the referral age threshold and increasing the index
of suspicion appear to be the only way of diagnosing this group (9% of the total) but
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such a strategy would be difficult to justify on cost grounds. Weight loss or anaemia
without GI symptoms represented 44% of those not meeting the guidelines. The
burden upon endoscopy services by the need to investigate these extra patients will
be compounded by the need to investigate all the other patients with worrying
symptoms but no malignant disease85'171'172'176. Preliminary results from other centres
would suggest that the pick up rate for the over 55 years of age with new dyspepsia
group is very low, whereas in this study the largest group of patients fell into this
category. Nevertheless, if these patients are not gastroscoped it will inevitably
diminish our ability to improve the detection rate of early disease103'178. Without
more endoscopy resources or better targeting of 'at risk' patients this study shows
that 1 in 5 patients will have their gastroscopy delayed even longer as two-week rule
patients are prioritised. Our results indicate younger patients (45-55 years of age) and
those with early disease and simple dyspepsia 103 will be disadvantaged unless the
current system changes.
The main limitation of this study is the lack of a denominator to be sure that adopting
these new strategies would not lead to an increase in urgent referrals with little
improvement in the overall delay in diagnosis
The NICE dyspepsia guidance document advocates investigation only for patients
with "alarm symptoms" (defined by NICE as GI bleeding, dysphagia, unintentional
weight loss and persistent vomiting) or those over 55 years with high risk factors
(defined by NICE as pernicious anaemia, previous gastric surgery or gastric ulcer) or
those taking NSAIDs. These guidelines are at odds with the Urgent referral
guidelines as they have no provision advocating endoscopy for patients with new
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onset dyspepsia. By adopting a high threshold for investigation the concern would be
that by diagnosis the patient will have advanced disease or at the very least have
endured a delay in diagnosis as a result of the now advocated "test and treat"
strategies.
The second issue relating to the two-week rule is the apparent reluctance ofGeneral
Practitioners to investigate patients over 55 years of age despite recent onset
dyspepsia. Half the patients seen in this category had been prescribed acid
suppression therapy, which is known to delay diagnosis further"5,147. If hospitals
have to improve access to endoscopy for these patients it is equally necessary for
GPs to identify 'at risk' patients and refer early when symptoms are not necessarily
indicative ofmalignancy. From a primary care perspective there is a conflict between
guidelines with respect to older dyspeptic patients
More 'open access' gastroscopy might seem to be the logical solution to this problem
and most units now offer such a service149, but present demand will be greatly
exceeded by increasing acceptance of the two-week rule. Whilst this may seem to be
a secondary care problem, the creation ofPrimary Care Trusts means that the
commissioning of these services will be theirs. In addition the crucial decision as to
whether a patient over the age of 55 years should be referred for gastroscopy,
irrespective ofwhether alarm symptoms are present or not, will impact most on
individual general practitioners.
In conclusion these findings indicate that the current referral guidelines will identify
only 72% of patients with UGI ACA at their initial GP visit. Patients with 'epigastric
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mass' represent only 2.4% of patients whereas patients with weight loss or iron
deficiency anaemia in the absence ofupper GI symptoms together constitute 12.3%
of patients.
The "two-week" referral guidelines are aimed at identifying patients with cancer and
so speed referral. Unfortunately the current guidelines are neither sensitive nor
specific and risk delaying the diagnosis in a significant number of patients. The
capacity to gastroscope more patients in the "at risk" age group (>55 years) could be
created by severely limiting access to those under this age (NICE). In addition GPs
should consider gastroscopy for any at risk patients with new onset symptoms. There
may well be a value to a "negative" endoscopy. By increasing the index of suspicion
and improving access to endoscopy it may be possible to improve the detection of
early stage disease and hence improve outcome.
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All (n=494) 6.7 (1-174) 65.4 2.6 (1-30) 46.4 71.9
Age >55 with dyspepsia/
heartburn/ reflux < 1 year
duration (n=244)
10.8(1-174) 48.8 2.8(1-17) 39.3 66.8




0.2 (1-5) 96.6 0.6 (1-9) 89.7 93.1
Dysphagia (n=l 15) 2.4(1-120) 86.1 2.5 (1-18) 44.3 78.3
Dyspepsia or epigastric
pain with weight loss
(n=49)
1.6(1-10) 83.7 3.0(1-22) 46.9 67.3
Dyspepsia or epigastric
pain with past history of
gastric surgery/ Barrett's/
dysplasia (n=23)
6.9(1-24) 43.5 3.1 (1-9) 43.5 60.9
Dyspepsia or epigastric
pain with anaemia (n=14)




6.6(1-34) 54.5 3.7(1-30) 72.7 72.7
Palpable mass (n=9) 0.1 (1) 100 1.0(1-3) 66.7 100
Table 3.1. Details of patients' symptoms are shown along with the time taken for
the General Practitioner to refer the patient to a specialist or open access
gastroscopy. The range, in brackets, refers to the time period within which the
patient was seen or referred.
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All (n=l 91) 7.1 (1-137) 62.3 2.8 (1-18) 49.2 69.6
Age <55 with dyspepsia or
heartburn/reflux or
epigastric pain (n=31)
17.7(1-137) 32.3 4.1 (1-18) 32.3 61.3
Age >55 with dyspepsia or
heartburn/reflux or
epigastric pain >1 year
(n=16)
26.9(1-126) 12.5 4.6(1-13) 37.5 43.8
Weight loss, no upper GI
symptoms (n=53)
2.5 (1-20) 69.8 2.4(1-16) 45.3 75.5
Anaemia, no upper GI
symptoms
(n=31)
2.8(1-40) 77.4 2.6(1-13) 48.4 67.7
Dyspepsia or epigastric
pain with anorexia (n=15)
4.1 (1-14) 60.0 1.7(1-8) 66.7 86.7
Fatigue and/ or Lethargy
(n=15)
4.0 (3-5) 80.0 1.5 (1-3) 53.3 73.3
Chest pain and/ or
breathlessness (n=10)
3.0(1-21) 80.0 3.0(1-12) 60.0 60.0
Collapse (n=9) 1.1(1-5) 88.9 1.0(1-5) 77.8 77.8
Nausea and vomiting (n=8) 1.3 (1-3) 100.0 3.0(1-18) 75.0 75.0
Lower abdominal pain
(n=3)
3.0(1-5) 66.7 1.0(1-3) 66.7 100.0
Table 3.2. Details of patient's symptoms are shown along with the time taken for
the General Practitioner to refer the patient to a specialist or open access
gastroscopy. The range, in brackets, refers to the time period within which the
patient was seen or referred.
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Chapter 4. Cancers missed at endoscopy.
4.1 Introduction.
Despite the widespread use of endoscopy, early gastric cancer remains uncommon in
•••113
the UK and delays to diagnosis may play some part in this picture . It has been
reported that as many as 1 in 6 oesophago-gastric cancers may be missed at
endoscopy within the 3 years leading up to diagnosis ,62'179 and that the prior use of
anti-secretory drug therapy may contribute to this delay115. This suggests that even if
the causes of the delays outlined in Chapters 2 and 3 are addressed, opportunities to
diagnose a significant number of these cancers earlier are being missed. In many
cases the failure to diagnose malignancy at initial gastroscopy will be a direct result
of inconclusive histology. Such patients are not 'missed' as the suspicion of
malignancy results in a second endoscopy and further biopsy. If the endoscopic
appearances are not 'suspicious' the patient's real pathology may be missed,
particularly if symptoms respond to acid suppression therapy. Gastric ulcers are
usually re-gastroscoped after 6-8 weeks treatment to ensure healing and exclude
malignancy. Again, a malignant gastric ulcer could not be deemed to have been
"missed" if diagnosed in this way, despite a delay of up to 8 weeks.
The "real" missed cases ofmalignancy are those not diagnosed at initial gastroscopy
and includes the following groups, some ofwhom might still have been diagnosed
within a short time of the initial gastroscopy:-
1. Patients with a normal gastroscopy or minor abnormality (oesophagitis,
gastritis, hiatus hernia, gastric polyp) and whose symptoms failed to resolve
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on treatment, relapsed on treatment or the patient developed new 'worrying'
symptoms and who subsequently had an unplanned follow up endoscopy;
2. Patients with a definite abnormality (erosions, ulcer)
a) where malignancy was detected at planned follow up in addition to the
previously diagnosed abnormality
b) where the abnormality was deemed to be benign, no biopsies taken or were
negative and no follow up was arranged
3. Patients with suspicious lesions but with negative histology who were not
followed up.
Thus some patients with short delays should still be classified as 'missed' whereas
some patients with long delays were not 'missed' because the suspicion remained
that the pathology was not representative of the clinical and/or endoscopic diagnosis.




The aim of this study was to determine the number ofpatients with upper GI
adenocarcinoma who were truly missed as a result ofnot being diagnosed with
cancer at their initial endoscopy and to examine the potential variables, including
operator experience, nature of prior reported abnormalities, biopsy/cytology rates and
prior anti-secretory drug therapy, that may have contributed
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4.3 Patients and methods.
The previously identified cohort of patients with oesophago-gastric adenocarcinoma
was studied. The records were reviewed (by SP and HO'F) to identify the
demographics of the cohort and details of the referral pathway. A "missed cancer"
was identified when there was a prior opportunity to diagnose the cancer within 3
years of diagnosis. If this penultimate investigation was endoscopy it was known as
the prior endoscopy. The above criteria were used to identify "real" missed cancers.
Records were reviewed to determine details of the operator, original endoscopic
diagnosis, frequency of biopsy and/or cytology samples and any previous
investigations. Data was collected on the prescribing of anti-secretory drug therapy.
All data was password protected and stored on a PC based spreadsheet/database only
accessible to the investigators. The data were entered and analysed using Epi Info™
epidemiological database and statistical analysis package (US department of Health
and Human Services, Centre for Disease Control and Prevention, Atlanta, Georgia,
USA). Accuracy of data entry was optimised using the double data entry (by two
different operators) and cross checking facility.
4.3.1 Statistics
Data was analysed using parametric methods for normally distributed continuous
data (t test, ANOVA) and non parametric methods (x , Kruskal Wallis) for
categorical data and non normally distributed continuous data. Results were
considered to be statistically significant with p values <0.05 (95% confidence limits).
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4.4 Results.
Of the 685 patients a prior investigation was recorded within 3 years of diagnosis in
242 (35.3%). In 183 patients (26.6%) the prior investigation was endoscopy (+/-
other investigation such as abdominal ultrasound scan or barium study). Details are
shown in table 4.1.
39 patients (5.7%) had 2 endoscopies within 3 years, and 18 (2.6%) had 3
endoscopies within 3 years.
There was no statistically significant difference in age, sex, or diagnosis between
those in the missed cancer group and the diagnosed at first endoscopy group.
4.4.1 Patients
At least one prior endoscopy was performed in 50 patients (25.3%) subsequently
diagnosed with oesophageal adenocarcinoma and 133 patients (27.3%) later
diagnosed with gastric adenocarcinoma (as shown in table 4.1).
4.4.2 Endoscopy.
The findings at the most recent prior endoscopy along with the macroscopic
appearance, with regards "suspiciousness" of the findings, are shown in table 4.3.
4.4.3 Endoscopist.
The diagnosis of cancer was made at endoscopy in 652 cases out of a total of 685
patients (194 oesophagus, 458 gastric). In 494 the diagnosis was made at the first
endoscopy (148 oesophagus, 346 gastric), and a senior endoscopist (consultant,
associate specialist, GP hospital practitioner) performed this in 68.6% of cases
(339/494).
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A total of 158 patients had at least one prior endoscopy where the diagnosis of cancer
was missed (46 oesophageal, 112 gastric), and a senior endoscopist performed the
endoscopy in 62.7% of these cases (99/158), with the remaining endoscopies being
performed by a trainee (p=0.2). Details in table 4.4.
4.4.4 Method of diagnosis of cancer after a prior endoscopy.
Where a prior endoscopy had failed to diagnose the cancer, the majority of cases
were subsequently diagnosed at endoscopy (158/183).
In 25 (13.7%) patients (four oesophageal, 21 gastric) the cancer diagnosis was not
made at gastroscopy but at surgery in 17, ultrasound (US) guided biopsy in four,
liver biopsy in one, endoscopic retrograde cholangiopancreatography (ERCP) in one,
abdominal US in one and with a barium study in one. In 80.0% (20/25) cancer was
suspected and the majority (84%) had the diagnosis made within 12 weeks.
Of the 502 patients who did not have a prior endoscopy, only 8 (0.2%) (0
oesophageal, 8 gastric) had their cancer diagnosis made by other means (five
surgery, two US guided biopsy, one ERCP) (p<0.00001).
4.4.5 Delay to diagnosis after a prior endoscopy.
The mean time to diagnosis after a prior endoscopy was 24.4 weeks (range 0-153).
Figure 4.1.
For those with oesophageal cancer the mean time from prior endoscopy to diagnosis
was 28.7 weeks (range 0-131). For those with gastric cancer the time from prior
endoscopy to diagnosis was 22.8 weeks (range 0-153) (p=0.19).
45.9% of patients (84/183) had the prior endoscopy within 6 weeks of the diagnostic
endoscopy (oesophagus 18/50 (36.0%), gastric 66/133 (49.6%). In 63.4% (116/184)
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the prior endoscopy was within 12 weeks (oesophagus 25/50 (50.0%), gastric 91/133
(67.7%) and in 68.5% (126/184) the prior endoscopy was within 16 weeks
(oesophagus 30/50 (60.0%), gastric 96/133 (72.2%). The remainder were delayed for
longer. There was no significant difference between the mean time to diagnosis in
oesophageal and gastric cancer cases overall but the difference in the median times
implies oesophageal cases more likely to be delayed longer.
4.4.6 "Real" missed cases
Using the criteria above there were 63 patients (9.2%) who were "truly" missed.
43 patients had a normal prior gastroscopy or had only minor abnormalities seen and
had symptoms that failed to resolve on treatment, relapsed on treatment or they
developed new 'worrying' symptoms and so had an unplanned follow up endoscopy.
One patient had a definite abnormality at the prior endoscopy but the malignancy
was only detected at the planned follow up in addition to the previously diagnosed
abnormality.
Two patients had a definite abnormality at the prior endoscopy but the malignancy
was only detected at an unplanned follow up and was unrelated to the previously
diagnosed abnormality.
12 patients had an abnormality (all gastric ulcers) deemed to be benign and either no
biopsies were taken or the histology negative and no follow up was arranged. The
diagnosis was made later at an unplanned further endoscopy.
Five patients had a suspicious lesion seen at the prior endoscopy but the histology
was negative. They were not followed up and were later diagnosed with malignancy
at an unplanned endoscopy.
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4.4.7 Biopsy and cytology rates.
Where a prior endoscopy had occurred a mean of 1.8 biopsies were taken (median 1,
range 0-14) (n=170, 2 missing data; 11 normal endoscopies with no biopsies taken
were excluded). In the 493 cases where the diagnosis was made by endoscopy at the
first opportunity (i.e. no prior endoscopy had occurred) the mean number of biopsies
taken was 3.8 (median 4 range 1-14).
Of the oesophageal cases that appeared to be potentially malignant at the prior
endoscopy, biopsies revealed worrying histology (cytological atypia or dysplasia of
any type) in 27.6% (8/29). Although the endoscopy showed a potentially malignant
lesion, biopsies were not taken in 24.1% (7/29). In the cases where the penultimate
endoscopy was normal or revealed a benign looking lesion no worrying histology
was obtained. In 47.4% (9/17 missing data in 2) no biopsies were taken.
Of the gastric cases, the penultimate endoscopy findings were considered potentially
malignant in 49.6% (66/133). In 30.3% (20/66) of the endoscopies where suspicious
findings were seen no biopsies were taken; 10 had unsatisfactory examinations and
10 had gastric ulcers. Of the gastric ulcers, 6 had active bleeding, 1 was on warfarin
and 2 had cytology taken. In one case where no biopsies were taken there was a
strong clinical suspicion ofmalignancy and the patient had a laparotomy with the
resected specimen confirming carcinoma. For those with potentially malignant
findings at the prior endoscopy, 24.3% (17/66) had worrying histology. For those
with benign looking lesions at the prior endoscopy none had worrying histology.
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Cytology was only taken in 34/170 cases (20%) and cytology rates varied according
to the findings at the prior endoscopy. In the case of oesophagitis 7/23 (30.4%) had
cytology taken, strictures 5/21 (23.8%), ulcers 31/71 (18.3%) and gastritis 2/14
(14.3%). When comparing lesions considered to be potentially malignant with those
that appeared benign, cytology rates were significantly higher in the potentially
malignant (30/100 vs. 4/70, p=00002).
Biopsy rates were similar for junior and senior endoscopists (senior mean 1.94,
median 2, range 0-14 vs. junior 1.94, 1, 0-8, p=0.9)
4.4.8 Antisecretory drug therapy
Of the 685 total, 326 (47.6%) had been prescribed antisecretory drug therapy prior to
diagnosis.
502 patients had their diagnosis made at the first opportunity and in 494 this was
made by endoscopy. Of those that were diagnosed by endoscopy at the first
opportunity 191/494 (38.7%) had been prescribed antisecretory drug therapy whereas
of the 183 cases where the diagnosis was not made at prior endoscopy, 93 (50.8%)
had antisecretory drug therapy prior to this endoscopy (p=0.005) i.e. those patients
who had a prior endoscopy were more likely to have been prescribed antisecretory
drug therapy.
Of the oesophageal cases (n=198), 85 (42.9%) had been prescribed antisecretory
drug therapy prior to diagnosis. 148 had their diagnosis made at the first opportunity
and in all cases this was made by endoscopy. Of those that were diagnosed by
endoscopy at the first opportunity 58 (39.2%) had been prescribed antisecretory drug
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therapy whereas of the 50 cases where the diagnosis was not made at the prior
endoscopy 27 (54.0%) had antisecretory drug therapy prior to this endoscopy
(p=0.07) i.e. no significant difference between prior endoscopy group and diagnostic
endoscopy group and antisecretory drug therapy prescription but a strong trend
towards misdiagnosis with AST use.
Of the gastric cases (n=487), 230 (47.2%) had been prescribed antisecretory drug
therapy. 354 had their diagnosis made at the first opportunity and in 346 cases this
was made by endoscopy. Of those that were diagnosed by endoscopy at the first
opportunity 133 (38.4%) had been prescribed antisecretory drug therapy whereas of
the 133 cases where the diagnosis was not made at prior endoscopy 66 (49.6%) had
antisecretory drug therapy prior to this endoscopy (p=0.03) i.e. those patients who




This study looked at the extent of the failure to detect oesophago-gastric ACA in
South Tees and has shown that in 35.3% (242) of patient's there was a prior
investigation within 3 years of the cancer diagnosis and in 26.7% (183) this was
endoscopy. In these patients the mean delay to diagnosis was over 6 months. On
examining the cases where there was a delay in diagnosis there were clearly two
groups of patients - (i) those where the diagnosis was delayed as the diagnosis was
not made at the first endoscopy but a follow up endoscopy was planned and (ii) those
where no follow up was planned and it took until the patient represented for the
diagnosis to be made - the "real" missed cases. These account for 9.2% of the total.
At the prior endoscopy abnormalities were reported in 92% of the patients (excluding
failed endoscopies and those reported as normal). It is beyond the ability of this
retrospective study to say that all the lesions seen were the precursors of the cancers
and clearly some findings were irrelevant to the final diagnosis. However, due to the
natural history of oesophago-gastric cancer, it is likely that in some patients
malignant lesions would have been present at the earlier endoscopy but were not
diagnosed. Almost certainly in the two thirds who had a prior endoscopy within 12
weeks of diagnosis a malignant lesion would have been present. Although this delay
is unlikely to have an effect on prognosis, given the natural history of oesophago-
gastric cancer, it is still unacceptable. The patient will have endured avoidable
investigations and the endoscopy service capacity will have been unnecessarily
reduced.
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If gastric ulcers alone are considered, all the cancers were diagnosed in the same
geographical area and thus this demonstrates that the problem is one of inadequate
biopsying. In 39% of cases it appears to be that lesions were detected but insufficient
biopsies are being taken to make the diagnosis, resulting in a requirement for a repeat
examination. Biopsy numbers were generally low and especially so if the lesion
appeared benign or the endoscopy was done as an emergency. Biopsy rates were well
below those shown in previous studies to be most likely not to miss cancer within an
ulcer. Considering the natural history of gastric cancer a delay of 12 weeks is
unlikely to effect prognosis but from the patient's perspective any delay is often
perceived as unacceptable and for endoscopy capacity these repeat endoscopies are
an avoidable wastage.
There are a number of factors why biopsies are not taken but this was not influenced
by the experience of the endoscopist. AST treatment was more commonly prescribed
in the "missed" group supporting the hypothesis that AST therapy allows lesions to
heal and so masking their true potential at endoscopy. It seems that an important
determinant as to whether biopsies are taken, or not, is the suspicion of the
endoscopist irrespective of the nature of the lesion.
In order to minimise delay and reduce the miss rate symptoms should be reviewed
regularly, AST not prescribed in high risk groups until after endoscopy and a high
level of suspicion maintained with a low threshold for endoscopy. Improved
endoscopic technique and a policy to perform multiple biopsies (seven or more)
when a lesion is seen, especially when it looks potentially malignant or represents
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April April April April April April April April April April
1991- 1992- 1993- 1994- 1995- 1996- 1997- 1998- 1999- 2000-
March March March March March March March March March March
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■ Oesophagus Proximal stomach Distal stomach —Extensive
Figure 4.1 Change in site over time.
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Months
Figure 4.2 Time from prior endoscopy to diagnosis.
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All UGI ACA Oesophageal Gastric
Total number 685 198 487
Male 451 143 308
Female 234 55 179
Mean age at diagnosis 70.3 (28-94) 69.4(41-94) 70.7
(range) in years (28-92)
Site of cancer at - Middle third 5% Proximal 45%





Overall 242 78 164
Endoscopy +/- other 183 (75.6%) 50 (64.1%) 133 (81.1%)
Barium studies alone 36(14.9%) 24 (30.8%) 12 (7.3%)
US Scan alone 23 (9.5%) 4(5.1%) 19(11.6%)
Site of "missed" - Middle third 1 OGJ (gastric side) 11
cancer at diagnosis Lower third 36 (8.3%)
OGJ (oesophageal Upper 36 (27.1%)
side) 13 Body 15 (11.3%)
Lower 58 (43.6%)
Extensive 13 (9.8%)
Mean time to diagnosis
in weeks following
prior endoscopy 24.4 (6, 1-153) 28.7(11, 1-131) 22.7 (6, 1-153)
(median, range)
Nature of finding at n=183(%) N=50 n=133
prior endoscopy
Normal 11 (6%) 1 10
Oesophagitis 25 (14%) 20 5
Gastritis 14 (8%) 1 13
GU 71 (39%) 2 69
DU 4 (2%) 1 3
Stricture 21 (11%) 18 3
Other 37 (20%) 7 30
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Normal 3 0 3
Oesophagitis 7 6 (severe or Barrett's) 1
Gastritis 7 0 7
GU 52 1 (at OGJ) 51
Dll 1 0 1 (also gastric erosions)
Stricture 17 15 2
Other 29 3 (suspicious mass 3) 26 (suspicious mass 5,




views ? tumour 1)
Nature of finding at n=67 N=25 n=42
prior endoscopy -
when diagnosis
delayed more than 12
weeks
Normal 8 1 7
Oesophagitis 18 14 4
Gastritis 7 1 6
GU 19 1 18
DU 3 1 2
Stricture 4 3 1
Other 8 4 (suspicious mass 1, 4 (mucosal abnormality
failed endoscopy 1, 1, polyp 1, hiatus hernia
hiatus hernia 2) 1, failed scope 1)
Table 4.1. Details of study cohort.
All UGI ACA Oesophageal Gastric
% patients
prescribed AST at 47.7 48.5 47.4
any time 57.8 65.6 54.5
% PPI 42.2 34.4 45.5
% H2RA





Table 4.2 Details of AST prescription.
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All UGI ACA Oesophageal Gastric
Macroscopic appearance of n=
findings at prior endoscopy
"potentially malignant" 95 29 66
"benign" 72 19 53
"normal" 11 1 10
Macroscopic appearance of
findings at prior endoscopy-
when diagnosis made within
12 weeks
"potentially malignant" 80 19 (oesophagitis 2, 61 (GU 36,
Barrett's 2, stricture gastritis 2,






"benign" 30 6 (GU atOGJ 1, 24 (DU 1, GU 15,
oesophagitis 2, gastritis 5,




"normal" 3 0 3
(Failed endoscopy 3)
Macroscopic appearance of
findings at prior endoscopy-
when diagnosis delayed more
than 12 weeks
"potentially malignant" 15 10 (oesophagitis 8, 5 (GU 5)
stricture 1, mass 1)
"benign" 42 13 (DU 1, GU 1, 29 (DU 2, GU 13,
gastritis 1, hiatus hernia 1,
oesophagitis 6, gastritis 6,
stricture 2, hiatus oesophagitis 4,





"normal" 8 1 7
(Failed endoscopy 2)
Mean time to diagnosis in
weeks after prior endoscopy if
findings considered
"potentially malignant" 7.5(2.5,0-91) 12.3 (4, 0-85) 5.4 (2, 0-91)
"benign" 40.2(17, 0-150) 49.3 (44, 0-131) 37 (15,2-150)
"normal" 74.5 (86, 5-153) 131 (131, 131) 68.8(68.5, 5-153)
at prior endoscopy
Table 4.3. Details of the macroscopic appearance and suspiciousness of the
findings at the prior endoscopy, and time to diagnosis.
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339 (68.6%) 99 (62.7%)
Registrar 120 (24.3%) 40 (25.3%)
SHO 5 (1.0%) 3 (1.9%)
Unknown 30(6.1%) 16(10.1%)
Table 4.4. Endoscopist performing procedure
Eventual site of cancer Biopsy rate at prior
endoscopy
Cytology rate
Oesophageal (n=47) 2.0,(2.0, 0-14) 27.7%
Gastric (n=123) 1.8,(1,0-7) 17.1%
Table 4.5. Biopsy and cytology rates.
Principal finding at prior
endoscopy
(n=183)




Oesophagitis 25 2.3, 2, 0-14 (n=23)
Oesophageal stricture 21 1.1, 1,0-3
"Gastritis" 14 1.9, 1.5,0-6
GU 71 2.0, 1,0-7
Emergency diagnosis 28 1.3,0.5,0-7
Non-emergency diagnosis 43 2.5, 3, 0-7
Benign looking polyp 1 1
Suspicious mass 10 2.9,3, 1-5
Mucosal abnormality 4 3.8,3.5, 1-7
Pyloric stenosis 6 2.3, 2.5, 0-5
Stomach full of food 8 0.6, 0, 0-3
Failed endoscopy 5 0
Table 4.6. Diagnosis at prior endoscopy and biopsy rates.
96
Chapter 5. Prospective evaluation of endoscopic
diagnosis in relation to histopathology for
patients with gastric ulcer disease.
5.1 Introduction
As shown in chapter 4, malignant lesions are "missed" at endoscopy and that even
when obvious lesions are seen, misdiagnosis occurs because insufficient biopsies are
taken or histology is misleading. Graham et al showed that one biopsy was sufficient
to make the diagnosis in only 70% of gastric cancers (93% of oesophageal cancers)
whilst four biopsies were required to be accurate in 95% of cases and seven biopsies
were required to ensure that no diagnosis was missed141. Ulcer healing drugs have




The aim of this study was to investigate prospectively whether the endoscopist's
assessment of the macroscopic appearance of a gastric ulcer was accurate and
whether this determined biopsy rates.
5.3 Patients and methods
The study was performed at James Cook University Hospital during the period
October 1999 until August 2001 with at least a 2-year follow up to ensure no patient
presented later with a 'missed' upper gastrointestinal carcinoma
All patients diagnosed as suffering from a gastric ulcer (mucosal breach >5mm)
during the study period were considered for inclusion. Theatre logbooks were also
examined to identify patients diagnosed with gastric ulcer at laparotomy. Ulcers
described as "superficial" or "small" were excluded.
Demographic and endoscopic details were collected for all patients including prior
treatment with antisecretory drugs. . Whether the ulcer was considered "benign",
"suspicious" or "malignant" by the endoscopist was recorded from information on
the endoscopy report and histology request. The endoscopist was not aware of this
process but did know that 'audit' was taking place.
Data was collected the following day (by SP) and results correlated with the
histological findings (including the number of biopsies received by the pathology
department).
Data handling and analysis was performed using the SPSS vl 1™ epidemiological
database and statistical analysis package.
South Tees Acute Trust Ethics Committee approval was obtained.
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5.4 Results
During the study period a total of 250 patients were diagnosed with gastric ulcer
disease ofwhich 196 met the inclusion criteria. Of these 32 (16%) were malignant
ulcers. Details are shown in table 5.1.
The mean age at the diagnostic endoscopy was 67 years (median 70, range 23-98).
The male: female ratio was 1.25:1.
5.4.1 Factors influencing the endoscopist's judgement
5.4.1.1 Location of ulcer
The majority of the ulcers were distal (66.8%). Details are shown in table 5.1.
5.4.1.2 Size
The larger the ulcer, the more likely the endoscopists were to regard the ulcer as
suspicious or malignant.
5.4.1.3 Experience
There was no difference between junior doctors' interpretation of ulcer appearances
compared to more senior endoscopists (table 5.2).
5.4.1.4 Previous antisecretory drug therapy
The predictive value of the endoscopist's macroscopic judgement regarding the
"suspiciousness" of an ulcer can be estimated as the proportion of correct
macroscopic diagnoses (PV pos). Details can be seen in table 5.2. The overall
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positive predictive value for suspicious or malignant looking ulcers was worse if
patients had been on antisecretory drug therapy prior to endoscopy
5.4.2 Follow up
5.4.2.1 Immediate
Of the 196 cases, 17 patients underwent laparotomy. 10 ulcers presented with
perforation requiring laparotomy. 7 patients required surgery for bleeding (6 patients
having a prior endoscopy - biopsies taken in only 1 case).
5.4.2.2 Long term
No patient has subsequently developed an upper gastrointestinal carcinoma over a
mean follow up of 3.4 years (2.5-4.4).
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5.5 Discussion
Gastric ulcer disease accounts for 4-5% of all gastroscopy findings 180 and is now the
commonest lesion seen at emergency gastroscopy performed to investigate upper GI
haemorrhage181. The endoscopist usually makes a judgement about whether an ulcer
looks "benign" or "malignant" based on a number of criteria. These include the
presence or absence of rolled edges, ulcer depth, size and position. That
interpretation, which may be subconscious, is influenced by numerous factors
including presentation and the endoscopist's experience. In the case of gastric
ulceration well-established protocols involve multiple biopsy of the ulcer to exclude
malignancy and then a follow up endoscopy of "benign" ulcers until healing. The
purpose of this study was to determine if the endoscopist's visual determination of
pathology in various clinical settings was accurate and whether this determination
influenced the number of biopsies taken.
The results suggest that the endoscopists' judgement was good with regard to benign
ulcers achieving an overall PVpos of 0.96. This was similar between junior and
senior endoscopists suggesting that the experience of the endoscopist did not
influence this judgement. The endoscopist was less adept at identifying "suspicious
or malignant" ulcers with a PVpos of only 0.58. The ability of the endoscopist to
determine if an ulcer was benign or suspicious appears to be influenced by treatment
with antisecretory drugs prescribed prior to endoscopy. In this situation the
endoscopist was less likely to recognise the ulcer as malignant suggesting that these
agents alter the endoscopic appearance ofmalignant ulcers. One factor influencing
the endoscopists' impression of an ulcer appeared to be size. "Malignant looking"
ulcers were four times larger than ulcers considered "benign looking" whereas
102
"suspicious looking" ulcers were twice as large. The determination of
"suspiciousness" also affected the ulcer biopsy rate with more biopsies being taken
from the "suspicious" or "malignant" looking ulcers.
Although this was a prospective study no attempt was made to alter the behaviour of
individual endoscopists as this may have biased the results. Clinicians were aware of
an "ulcer audit" but not the purpose of the study.
This study is limited by an incomplete data set and the subjective nature of some
data. For example, we do not know how "suspicious" the endoscopist really was that
malignancy might be present as this group clearly contains many ulcers that turned
out to be benign. In many cases details such as 'rolled edges' or ulcer depth were not
recorded. However as we did not wish to influence the endoscopists' opinion we
accepted this limitation to the study, particularly as this sort of data is often
incomplete. Paradoxically fewer biopsies were taken in the 'suspicious' group than
those thought to be definitely malignant. It would be clinically more appropriate to
increase the number of biopsies in this group rather than take a greater number of
biopsies in patients where the endoscopist is more confident that an ulcer is
malignant.
Another finding from this study relates to the small number of biopsies taken from
'benign' looking ulcers. In the emergency situation it is perhaps not surprising that
the focus of the procedure was on treatment rather than diagnosis but lack of a biopsy
protocol in this situation did result in 6 cancers being missed initially. Ulcer size
appeared to be a factor in determining biopsy rates and small ulcers (5-10 mm) were
biopsied less and very few ulcers were biopsied seven times, irrespective of size.
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In conclusion this study has shown that endoscopists are good at diagnosing benign
ulcers taking fewer biopsies but mis-diagnosing 4.4% (6/137) of cancers. Or for
every 20 ulcers considered to be benign one will actually be malignant.
"Suspiciousness" of malignancy appears to relate to ulcer size as well as appearance
although inadequate numbers of biopsies are taken compared to frankly malignant
looking ulcers. Finally, antisecretory drug therapy does appear to mask the
endoscopic appearance of "malignancy" making this a less likely endoscopic
diagnosis. We are now encouraging endoscopists to increase the biopsy rate for
patients with "suspicious" ulcers. In the emergency situation biopsy should be
performed once endoscopic therapy has been completed, or a repeat gastroscopy
should be performed prior to discharge in order to obtain biopsy material.
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Ulcer All "Looked "Looked "Looked
n=196 benign" suspicious" malignant"
Diagnosed by
Junior endoscopist 97 73 16 8
Senior endoscopist 80 60 11 9
(missing data n=19)
Diagnosed at
List 73 48 14 10
Open access 28 21 3 4
Emergency 82 66 11 3
PEG 2 2 0 0




Mean size (mm) 16.7 11.5 24.3 41.8
(median, range) (10,5-100) (10,5-60) (20, 5-100) (42.5, 6-90)
Location (n=)
OGJ 12 6 4 2
Proximal 49 35 7 6
Distal 123 91 17 8
Biopsy rate 70.0 (133/190) 62.1 (82/132) 96.2 (26/27) 87.5 (14/16)
(% of endoscopies where
biopsies taken)
List 95.4 (63/66) - - -
OAG 96.4 (27/28) - - -
Emergency 38.0 (30/79) - - -
Number of biopsies 2.2, 2, 0-6 1.8, 2, 0-6 3.6, 4, 0-4 4.2, 4, 0-6
(mean, median, range)
List 3.2,3,0-6 2.6, 3, 0-6 4.4, 5, 1-6 4.0, 4, 0-6
OAG 3.4, 4, 0-6 3.0, 3, 0-5 4.0, 4, 4 5.3, 6, 3-6
Emergency 1.0, 0, 0-6 0.75, 0, 0-4 2.4, 2.5, 0-5 3.3,4, 0-6
Sclerotherapy rate at 34.1 (28/82) 37.9 (25/66) 37.5 (3/11) 0 (0/3)
emergency endoscopy (%)
Patients taking AST prior to 21.4 (40/187) 21.6(29/134) 32.0 (8/25) 12.5 (2/16)
diagnosis (%)
Table 5.1. Ulcer demographics.
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Positive predictive value of macroscopic
judgement
Benign Suspicious or malignant
Junior 0.96 (70/73) 0.63 (12/19)
Senior 0.95 (57/60) 0.6(12/20)
All 0.96(131/137) 0.58 (26/45)
+AST 0.93 (27/29) 0.3 (3/10)
-AST 0.97(102/105) 0.65 (20/31)
List 0.94 (45/48) 0.59(14/24)
+AST 0.85(11/13) 0.67 (2/3)
-AST 0.97 (31/32) 0.61 (11/18)
OAG 1.0(21/21) 0.71 (5/7)
+AST 1.0(13/13) 0.5 (1/2)
-AST 1.0 (8/8) 0.8 (4/5)
Emergency 0.95 (63/66) 0.50(7/14)
+AST 1.0 (3/3) 0.4 (2/5)
-AST 1.0 (61/61) 0.5 (4/8)
Table 5.2. Positive predictive value of endoscopic judgement.
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Figure 5.2 (b). Endoscopic appearance and the effect of AST by type of
diagnostic list.
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Chapter 6. Prospective study of the use of
chromoendoscopy.
6.1 Introduction.
Endoscopy is considered to be the "gold standard" in the diagnosis of luminal upper
gastro-intestinal disease being superior to radiological techniques 182-1 85 but as shown
in chapters 4 and 5 lesions are being missed and inadequately biopsied. In addition to
this are we missing subtle mucosal abnormalities?
In Japan and elsewhere, chromoendoscopy (also known as dye-scattering,
chromoscopy, dye staining, vital staining), is widely used to improve the detection of
subtle mucosal changes which may represent early malignant lesions125'126'128-
130,133,186 ancj tQ delineate the mUcosa187.
Chromoendoscopy is not routinely utilised in the UK and thus there is no published
data regarding its efficacy in improving the endoscopic detection rate of clinically
significant lesions when used in the UK.
Although endoscopists are encouraged to biopsy all irregularities within the stomach,
to avoid missing early gastric cancer, in reality this strategy is likely to overwhelm
the currently available pathology services in many hospitals. Indeed the Royal
College of Pathologists have recognised this and recently published a report which
188advocates taking a biopsy ofonly clinically significant lesions .
6.2 Aim
This prospective study aimed to investigate the detection rate of additional clinically
significant lesions, in a symptomatic population over the age of 50 years referred for
open access endoscopy, by utilising chromoendoscopic techniques and to assess the
impact on pathology services of a rigorous biopsy policy.
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6.3 Patients and methods
All patients aged 50 years or over with upper GI symptoms referred for open access
endoscopy to the James Cook University Hospital were eligible for the study during
the period October 1999 until June 2001. The cancer referral guidelines advocate
investigation of dyspepsia in those over 55 years when the symptoms are of recent
onset although the guidelines allowed for this age to be lowered if thought
appropriate locally. In this study we chose a lower age for pragmatic reasons to
ensure that during the period of research an adequate number of patients would
undergo chromoendoscopy.
Local Ethics Committee approval was obtained.
A patient information sheet explaining the nature of the study was enclosed with the
appointment letter sent from the hospital. On arrival at the endoscopy centre the
patients were clerked by the nursing staff and the study further explained. Patients
who then did not wish to participate in the study underwent a standard endoscopy.
Those who wished to participate in the study were consented by the investigator (SP)
and an endoscopy was performed using local anaesthetic throat spray (1%
lignocaine) or intravenous midazolam, depending on patient preference. The patient
then underwent a "standard" endoscopy using an Olympus videoendoscope (XQ230,
Q200, XP240, XQ240, T240) linked to an Olympus CV240 processor and the
findings recorded. In the absence of contra-indications buscopan 20mg iv (repeated if
necessary to a maximum dose of 40mg) was used ifmucosal views were sub-optimal
as a result of gastric contractions. The stomach and any Barrett's oesophagus
identified was then sprayed, using an Olympus dye spray catheter (PW 6P-1, PW5L-
1) placed through the biopsy channel, with up to 20mls of a 0.5% methylene blue
solution (Martindale pharmaceuticals, Romford) containing 0.5ml simethicone
(Infacol™, Pharmax Ltd, Bexley), after surface mucus had been cleared with
simethicone (diluted up to 20mls). The spraying was performed from the pylorus
proximally in a helical pattern with retroversion of the endoscope to spray the
proximal stomach. The whole stomach was sprayed. Excess pooled dye was
aspirated. Discrete changes in surface contour or discolouration compared with
surrounding mucosa were recorded using was a Sony digital still mini-disc recorder
(DKR 700P). Biopsies from identified areas were sent for routine histological
analysis.
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Between patients the endoscope was cleaned as per BSG guidelines .
Patients were warned of the potential for discolouration of their urine and stools.
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6.4 Results.
A total of 1008 patients, from 65 GP practices, were studied with a mean age of 62.8
years (range 50-88, median 61.8 years). There were 450 males with a mean age of
63.3 years (range 50-88) and 558 females with a mean age of 62.3years (range 50-
87).
6.4.1 Risk factors
All patients were over 50 years of age and 518 patients (51.4%) reported regular
alcohol intake with a mean intake of 11.9 units per week (median 7.0, range 1-70
units) (men mean 15.8, median 12, range 0-70, women mean 6, median 4, range 0-
40). Two hundred and five patients (20.3%) were smokers (mean 14.3 cigarettes/day,
range 1-60).
6.4.2 Symptoms and prior treatment.
The nature of the symptoms at the time of the endoscopy is shown in table 6.1.
Acid suppression therapy (AST) was prescribed for 487 patients (48.3%) prior to
endoscopy of whom 231 were prescribed H2RA and 288 a PPI (with 32 having been
prescribed a H2RA earlier). A quarter (254) of patients had been prescribed a
NSAID.
For those prescribed PPI the median duration of treatment prior to endoscopy was 61




In 982 cases the referring GP stated the expected diagnosis or diagnoses as shown
table 6.2. Gastric cancer was considered as a possible diagnosis in only 3.0% of
referrals.
6.4.4 Endoscopy
Topical anaesthesia was used in 48.9% of endoscopies. Buscopan iv was used in
19.6% of cases.
The mean time taken to complete chromoendoscopic examination of the upper
gastro-intestinal tract was 14.7 minutes (median 15, range 2-30).
6.4.5 The findings with "standard" endoscopy.
Details of the findings are shown in table 6.3 and compared with the historical
findings of the open access service in figure 6.1.
6.4.6 Extra findings within the stomach with chromoendoscopy.
Extra findings were present in 142 patients, 14% of endoscopies of which 100%
were benign.
Details are shown in tables 6.4 and 6.5.
Examples of chromoendoscopy shown in figure 6.2.
6.4.7 Upper GI cancer
A total of 17 patients (1.7%) had upper GI cancer as shown in table 6.3. All were
detected on initial endoscopy prior to the use ofmethylene blue.
Barrett's oesophagus was found in 33 patients none ofwhich showed any
abnormality on chromoendoscopy.
6.4.8 Findings "missed/masked" by chromoendoscopy.
After a mean follow up of 3.1 years (median 3.14. range 2.2-3.9) there have been 2
patients subsequently diagnosed with oesophago-gastric adenocarcinoma. In both
cases the diagnosis was made within 8 weeks. In one case the patient could not be
intubated with throat spray but endoscopy was successful with sedation; the second
patient had extensive gastric erosions and was brought back for repeat endoscopy to
ensure healing. It was at this follow up endoscopy that the superficial cancer (not
seen on the original endoscopy) was diagnosed at the oesophago-gastric junction.
6.4.9 Pathology workload.
After chromoendoscopy an extra 326 biopsies were taken (mean 2.3 per endoscopy,
1-7). This equates to 3.7 weeks of extra work for the pathologists.
The number of clinically significant diagnoses was not increased by the extra
biopsies taken after chromoendoscopy.
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6.5 Discussion
In this study chromoendoscopy, with methylene blue used to detect additional
clinically significant findings at upper GI endoscopy, was evaluated in a population
aged over 50 years. This age group was chosen to yield a significant number of
patients in whom it was expected there would be a reasonable chance of identifying
pathology. Methylene blue in this study was used as a contrast dye to delineate the
surface topography. It was decided to use methylene blue as opposed to indigo
carmine, the usual contrast agent used to visualise the stomach, as it was readily
available and it had a favourable side effect profile.
Chromoendoscopy proved to be easy to perform in the endoscopy unit without
significantly prolonging the duration of the endoscopy and without any
complications or adverse events.
A rigorous biopsy policy was adopted for this study. Widespread adoption of such a
policy would clearly have practical implications due to the concerns surrounding
potential transmission of vCJD in endoscopy and thus the move towards more costly
disposable biopsy forceps.
There were additional findings noted in approximately 15% of the endoscopies
performed. Of these potentially pre-malignant lesions were detected in 45 cases
(31.7%). There is currently no accepted evidence for surveillance of these lesions
however Whiting et al showed that with annual follow up endoscopies for atrophic
gastritis and intestinal metaplasia the risk ofmalignancy was 11%. Thus they have
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suggested that there should be a multicentre randomised control trial to examine the
or
benefit of surveillance for these premalignant lesions ".
As expected given the sample size and relative low incidence of gastric
adenocarcinoma, along with the selection bias of the population studied, it was not
possible to show an improvement in the detection of malignancy.
Follow up of these patients has shown that in one patient a significant lesion was
missed at endoscopy. In this case a junctional tumour was diagnosed at a routine
planned follow up endoscopy. Although all patients underwent a "standard"
endoscopy prior to the use of the dye spray it is worth considering that dye does pool
in the fundus and care should be taken to ensure that the proximal stomach is
adequately visualised.
Thus, although chromoendoscopy did not reveal extra cancers it was useful to
delineate the surface of the stomach and highlighted areas of potential abnormality. It
proved practicable for day-to-day use and without side effects.
The extra burden generated however for the pathology department was significant,
amounting to almost a month of a pathologist's time. In an era where pathology
departments are under significant workload and staffing pressures it is hard to justify
the extra work generated as a result of the "biopsy everything" ethos when the yield
of significant pathologies was so low. If no biopsies had been taken at all from subtle
mucosal abnormalities the mis-rate of early gastric cancer would have been 1 in 1000
patients endoscoped.
Using a "gold standard" method to identify small or subtle mucosal lesions seems not
to be routinely worthwhile and simply adds to the burden of G1 pathologists. It
appears that early lesions are not being missed in any significant number. The main
problem as outlined in chapter 4 is the failure to biopsy an obvious lesion because it
looks benign.
Apr 92 Apr 92 Apr 93 Apr 94 Apr 95 Apr 96 Apr 97 Apr 98 Apr 99 Apr 00
- Mar - Mar - Mar - Mar - Mar - Mar - Mar - Mar - Mar - Mar
93 93 94 95 96 97 98 99 00 01
—Oesophageal ulcer —m— Oesophageal cancer GU
—Gastric cancer Overall DUD
Figure 6.1 Comparison of historical open access findings and findings during
research period.
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Fig. 6.2 (a). Early gastric cancer (a) before dye spray (b) after dye spray.
Figure 6.2 (b). Mucosa before dye spray (a) after dye spray showing intestinal
metaplasia
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Figure 6.2 (c). Raised lesion seen after chromoendoscopy.
Figure 6.2 (d). Polyps delineated by chromoendoscopy.
Figure 6.2 (e). Gastric mucosa (a) before dye spray (b) after dye.
N= %
Epigastric pain 694 68.8
Heartburn 452 44.8




Wt loss 75 7.4
Dyspepsia 6 0.6
Dysphagia 7 0.7






ble 6.1 Symptoms at time of endoscopy
Number %
GERD 476 48.5
Hiatus hernia 205 20.9
Not known 158 16.1
Duodenal ulcer 147 15.0
Gastric ulcer 123 12.5
Normal 47 4.8
Gastric cancer 29 3.0




Oesophagitis- grade 1 119
Oesophagitis- grade 2 119
Oesophagitis- grade 3 31













Oesophagus Squamous carcinoma 4
Adenocarcinoma 3
Small cell cancer 1
Stomach Adenocarcinoma 7
Early gastric cancer 1 (14%)
Lymphoma 1
Unable to intubate in 3 eases, endoscopy abandoned (food residue, patient intolerance) in 6 cases.
Table 6.3 Findings with standard endoscopy.
Nature of finding Number
Raised mucosal abnormality 19
Polypoidal lesion 36
Flat mucosal abnormality 33
Depressed lesion/erosion 37
Raised erosion 10
Other (scar, prominent fold) 7





Incomplete intestinal metaplasia 3
Complete intestinal metaplasia 0




Table 6.5. Histological findings from extra biopsies.
Chapter 7 Conclusions
Flexible fibreoptic examination of the upper GI tract has been part of standard
clinical practice for over 30 years. During this time, the incidence of upper GI
adenocarcinoma has slowly declined but mortality has remained stubbornly high
with a depressingly low 5-year survival, little different from the time when the
barium meal was the standard investigation of the upper GI symptoms. Changing
patterns of disease (decreasing distal gastric cancers and increasing numbers close to
the cardia) do not explain the failure to improve prognosis but the prognosis of early
gastric cancer is acknowledged to be very good with a 5-year survival rate in excess
of 90%. Why have modern endoscopic methods of diagnosis not had any impact on
the outcome of this truly awful disease and is there any prospect of improving the
situation during the next 30 years?
A major factor in the UK is the late presentation of upper GI cancer and this thesis
was concerned with clarifying and resolving the issues pertinent to this. Each chapter
has addressed a different contributory element:-
• Quantifying the time course to diagnosis of oesophago-gastric adenocarcinoma in
the South Tees population.
• Evaluating the effect of antisecretory drug therapy on the diagnostic process and
the delay that antisecretory therapy engenders.
• Examining the long-term outcome of these delays in the clinical context.
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• Analysing the effect of various strategies to improve early diagnosis, in particular
the implementation of the Urgent Referral Guidelines for upper GI cancer,
known more commonly as the "two week rule" guidelines.
• Identifying why not all upper GI cancers are diagnosed at the first endoscopy.
• Determining how many upper GI cancers are truly missed at endoscopy and how
many are simply not diagnosed, even though an endoscopic abnormality is
clearly recorded in the endoscopy report.
• Investigating the use of chromoendoscopy on the gastric mucosa to identify
minor abnormalities which might represent early gastric cancer and determine the
effect of an aggressive biopsy policy in patients "at risk" by virtue of age.
and
• Investigated the endoscopists' evaluation of histopathology from the appearance
of gastric ulcer disease.
The research that forms the basis of this thesis has confirmed that there are
unacceptable delays in the diagnosis of upper GI adenocarcinoma in the UK. The
time from first symptom to diagnosis has been shown to be 30 weeks, with patients
spending twice as long in the primary care phase of the diagnostic pathway as
compared with the secondary care phase. Patients with oesophageal cancer take
longer to present to their GP and longer to be seen in secondary care as a result of the
more "benign reflux-like " nature of their symptoms. The interpretation of the
patient's symptoms by their GP and the patient's perception of their presenting
symptoms is crucial to the diagnosis of the patient with cancer. Much effort has been
made to use symptoms to identify patients at most risk of cancer through the "2 week
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rule urgent referral guidelines". However this thesis has shown that only 50% of
patients present to their GP with "alarm" symptoms and only 78% of patients have
"alarm" symptoms at diagnosis. Over time patients with "benign" symptoms develop
"alarm" symptoms and are referred but using "alarm" symptoms alone as the trigger
for referral is associated with a delay in diagnosis. Patients with "benign" symptoms
were prescribed powerful acid suppressing medications prior to referral for
endoscopy, which was often delayed as a result. Surprisingly patients with "alarm"
symptoms were also treated, although less often. This treatment was initiated at the
patients' first visit to the GP and delayed diagnosis by 18 weeks. Over this time
patients with "benign" symptoms developed "alarm" symptoms but patients with
"alarm" symptoms did not have resolution of their symptoms. It might be anticipated
that widespread use of powerful acid suppressing drugs would inevitably delay
diagnosis in treated patients by a sufficient amount as to worsen prognosis compared
to their untreated counterparts. However work in this thesis did not show this and
those given treatment did not experience a worse outcome.
As stated earlier, the "2 week urgent referral guidelines" were introduced to speed
referral, for out patient review and investigation, those patients with "alarm"
symptoms. This thesis demonstrates that a significant number of patients with an
ultimate diagnosis of upper GI cancer did not meet the referral criteria at their first
GP visit or indeed at diagnosis. Extending these criteria to include patients with
unexplained weight loss and anaemia would improve this but would be unlikely to
improve prognosis as such symptoms denote advanced disease. The newly released
NICE dyspepsia guidelines (www.nice.org.uk) advocate the investigation of these
two groups of patients only ifdyspepsia is present but do not recommend
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investigation of those with new onset dyspepsia without a therapeutic trial ofH.
pylori eradication therapy or acid suppressing medication first. With this approach
there is a danger of delaying the diagnosis further in this group of patients (which is
the largest group identified in this thesis). Clearly these NICE dyspepsia guidelines
are aimed at reducing unnecessary gastroscopy but they do so at the very great risk of
decreasing still further our ability to diagnose upper GI malignancy at an early
(potentially curable) stage. New strategies need to be developed to identify high-risk
patients who would qualify for endoscopy before developing classic "alarm"
symptoms.
The delays in the referral pathway are only one element in the overall delay in
diagnosis. Essential to the process of diagnosing the upper GI adenocarcinoma is
endoscopy. This thesis has demonstrated that over 1/3 of patients have had prior
investigations in the 3 years prior to when the diagnosis was made. In three-quarters
of these cases the prior test was endoscopy. When all reasons why a diagnosis was
not made at the initial endoscopy were considered, 10% of patients had their cancer
truly "missed" at endoscopy. These patients represented later and were diagnosed.
The larger group who were delayed and diagnosed at a planned follow up endoscopy
constitutes a huge waste of endoscopic resource. The reason these cancers were not
diagnosed at the first endoscopy was not inexperience of the operator (most
endoscopies were performed by senior doctors) or that lesions were not seen (in the
majority of cases) but rather that insufficient biopsies were taken from lesions that
were in the main ulcerated. Acid suppressing medication may play a role by
"masking" the true nature of a lesion under a blanket of benign-looking re-
epithelialisation.
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The use of chromoendoscopic techniques to examine the gastric mucosa yielded
extra findings in 14% of endoscopies performed in a high-risk population (those over
55 years). All the lesions biopsied were benign although 1/3 were potentially pre-
malignant lesions. The rigorous biopsy policy used generated 3.7 weeks extra work
for the pathologists which is hard to justify given that no extra cases ofmalignancy
were found and considering the results from the retrospective review, which
suggested that even obvious lesions are being seen but not being diagnosed due to
lack of biopsies. The inability to diagnose obvious lesions, through inadequate
biopsies, needs to be fully addressed before time and effort is spent looking for subtle
lesions. In some instances when there was an obvious lesion biopsies were not taken
at all, or the biopsies taken were inadequate in quantity or quality. It is apparent,
from the data presented in this thesis on gastric ulcer biopsy rates, that the
endoscopist, when looking at a lesion makes a decision (which may be subconscious)
as to the nature of the lesion and its malignant potential. This operator bias has been
shown in this thesis to influence the number of biopsies that are taken. More biopsies
were taken form "suspicious-" or "malignant-looking" ulcers than from "benign-
looking" ulcers. However the endoscopists' ability to tell whether an ulcer was
"benign" or "malignant" was poor. This ability was hampered further by acid
suppressing medication, which reduced the positive predictive value of the
macroscopic judgement. It seems likely therefore that this type ofmedication does
alter the macroscopic appearance of ulcers in some way such that it influences the
endoscopist.
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In summary, patients delay seeing their GP with symptoms and because of the often
benign nature of those symptoms referral is delayed especially if the patient is treated
with acid suppressing medication. Further delay occurs because the cancer is not
diagnosed at endoscopy due to inadequate biopsies being taken. The NICE dyspepsia
guidelines will not improve the outcome of patients with oesophago-gastric cancer as
patients with early disease lacking "alarm symptoms" will not be offered an
endoscopy and those that are eventually investigated will have been on acid
suppression for some time. Some of the data from this thesis may influence the
debate on this subject.
If the delay in the diagnosis of upper GI cancer is to be improved patients with upper
GI symptoms who are "at risk" should be endoscoped irrespective of the nature of
the symptoms. An adequate number of biopsies should be taken from the lesions
routinely as part of a biopsy protocol. Acid suppressing medication should be
withheld until after endoscopy.
The difficulty is identifying the "high risk" population given the extremely high
prevalence of dyspepsia in the population and balancing the cost-benefit of any
strategy that increases endoscopy demand. As symptoms fail to discriminate those
with early malignancy, which is the group most likely to benefit from diagnosis, a
new approach is needed if outcome is to be improved. This should focus on reducing
the incidence of upper GI cancer in the population through risk reduction strategies
and be linked to a new method to identify "at risk" individuals through multifactorial
risk profiling.
Current strategies are more likely to worsen survival by excluding curable patients
from early investigation and despite the NICE guidelines the debate is far from over.
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The results of the studies outlined in this thesis will inform that debate and in
particular re-examine the guidance that new onset dyspepsia (without "alarm"
symptoms) in the over 55 year age group does not require endoscopy.
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Appendix I. GASTRIC CANCER STUDY
Study Number CANCER) ID Practice Code
D number DNUMBER NHS number
Name FIRSTNAME SURNAME Address
Date of birth DOB
Sex SEX Male D M Female D F Postcode
POSTCODE
SECTION A - CANCER DIAGNOSIS
Date cancer diagnosed DATECANCER Age at diagnosis in years AGEATDIAGN
Diagnosis investigation CANCERINVE
Barium Studies D db Gastroscopy DdG Other D do If other, please specify otherinves
Diagnosis DIAGNOSIS Squamous carcinoma oesophagus D SCO
Adenocarcinoma oesophagus Q ACO
Adenocarcinoma stomach Q ACS
Other □ OTH
If other please specify histology and site HISTOLOGYS
Symptoms at time of cancer diagnosis Dyspepsia / Heartburn /Reflux D 1
CANCERSVMP Epigastric Pain ± other symptom(s) D 2
Heamatemesis + Melaena D 3
Other □ 4
If other please specify OTHERSYMPO
(e.g. Anaemia, Dysphagia, Vomiting, Weight Loss, Early Satiety)
IfGastroscopy. CANCEROGD OAG D 1 List D 2 Emergency D 3
Operator name OPCANCER Number of gastric biopsies taken INDEXBIOPS
Cytology taken INDEXCYTOL Yes □ Y No □ N
Result CYTOORES Malignant D M Benign D B
Naked eye appearance of lesion NAKEDEYEO
Protuberant mass D 1 Ulcerated lesion D2 Mucosal abnormality D3
Oesophageal stricture D 4 Other D 5 If other, please specify OTHEREYEO






Time from consultation to cancer diagnosis
Was the patient on concurrent Aspirin or NSAIDs NSAIDINDEX
GPINDXTIME weeks
Yes □ Y No □ N
Patient on AST in time from consultation to cancer diagnosis ASTINDEX YesD Y No D N
If Yes, Time from consultation to AST initiated ASTTIMEO weeks
Duration of AST prior to cancer diagnosis DURATIONO weeks
Which medication? H2RA0 H2RA □ for H2RAWEEKS0 weeks H2RASCRIP0
Monthly scripts
PPIOPPI □ for PPIWEEKSO weeks PPISCRIPTO
Monthly scripts
Was treatment stepped up from an H,RA to a PPI in this time? STEPUPO Yes D Y No D N
Was treatment stopped by GP prior to cancer OGD? STOPGPO Yes Dy No D N
If Yes.. Date stopped STOPDATEO No. of weeks prior to cancer OGD STOPWEEKSO




Was cancer suspected by GP at this time GPSUSPECT YesH Y No D N
Previous GI investigation within 3 years of cancer diagnosis? PREV3YRS
Yes □ Y No □ N
If Yes, continue with section B If No, go to section C
SECTION B - PREVIOUS GI INVESTIGATIONS WITHIN 3 YEARS
Investigation(s) INVESTIGAT
Barium Studies D I Gastroscopy D 2 Other D 3 If other, please specify
1NVES3YRS
If Barium Studies is Yes, Date performed BARIUMDATE Age in years BARIUMAGE
BARIUMDIAG















If other please specify
IfGastroscopy is Yes, number of gastroscopies within last 3 years OGDLAST3Y
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Details of previous gastroscopies (in reverse date order from cancer
OGD)
GASTROSCOPY 1
Date previous gastroscopy 1 DATEGASTI Age at gastroscopy 1 AGEGAST 1
Operator name OPGAST1 GAST1TYPE OAgD 1 ListD 2 EmergencyD 3












□ 6 Grade 1,2,3,4,5 GAST1GRADE
Oesophageal Stricture D 7
□ 8Other
If other please specify GASTIOTHER
Number of gastric biopsies taken GAST1B1POS
GAST1CYTO Cytology taken Yes Dy No □ N
CYTOIRES Result Malignant Q M Benign □ b
Naked eye appearance of lesion NAKEDEYE1
Protuberant mass Dl Ulcerated lesion D 2 Mucosal abnormality D 3 Oesophageal stricture D 4
Other Us If other, please specify OTHEREYEI
□y No Dn Don't knowCLOl Clo taken Yes
□u
CLOl RESULT Result Positive Oy Negative Qn Don't know
□u
Any other relevant diagnosis at OGD? GAST1SECON
No □ 0 DU □ 1 Oesophagitis Ch HH □ 3
Other □ 5
Stricture CU





PPI Dp for GASTl WEEKS weeks
Eradication De
Symptoms on referral for investigation Dyspepsia / Heartburn /Reflux Ul
GAST1SYMPT Epigastric Pain ± other symptom(s) Ch
Heamatemesis ± Melaena Do
Other CU
If other please specify OTHERSYMP1
(e.g. Anaemia, Dysphagia, Vomiting, Weight Loss, Early Satiety)
Date first GP consultation with symptoms this episode GPDATEI
Time from consultation to OGD 1 GPTIMEI weeks
Was the patient on concurrent Aspirin or NSAIDs NSAIDI YesD Y No Dn
Patient on AST in time from consultation to OGD 1 AST1 YesD Y No Dn
If Yes, Date start of AST (antisecretory therapy) prior to OGD 1 AST1 DATE
Time from consultation to AST initiated ASTTIME1 weeks
Duration of AST prior to OGD 1 DURATION1 weeks
Which medication this episode? H2RA1 H2RA Dfor H2RAWEEKS1 weeks H2RASCRIP1
PPI1 PPI Dfor PPIWEEKSI weeks PPISCRIPI
Was treatment stepped up from an H2RA to a PPI in this time? STEPUP1 Yes D Y No D N
Was treatment stopped by GP prior to OGD 1? STOPGP1 Yes D Y No Dn
If Yes.. Date stopped STOPDATE1 No. of weeks prior to OGD STOPWEEKS1




No. of (monthly) prescriptions of AST in time period from OGD 1 to cancer OGD
SCRIPTASTI
No. of (monthly) prescriptions of AST type H2RA ASTTYPEHI PPI
ASTTYPEP1
Therefore, AST ASTTREAT1 NoneD N Continuous!!] C Intermittent!!!! I
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Time from OGD 1 to diagnosis of cancer OGD1 INDEX weeks
Did the patient have another OGD prior to OGD 1 (within 3 years of Cancer OGD)?
OTHEROGDI
Yes □ Y No □ N
If YCS, continue with section B If No, go to section C
GASTROSCOPY 2
Date previous gastroscopy 1 DATEGAST2 Age at gastroscopy I AGEGAST2
Operator name OPGAST2 GAST2TYPE OAgD 1 List D 2 EmergencyD 3


















GAST20THERIf other please specify
Number of gastric biopsies taken GAST2BIPOS
GAST2CYTO Cytology taken Yes oy No 0 n
CYT02RES Result Malignant □ M Benign □ b
Naked eye appearance of lesion NAKEDEYE2
Protuberant mass Dl Ulcerated lesion 0 2 Mucosal abnormality 0 3 Oesophageal stricture D
Other D 5 If other, please specify OTHEREYE2
□y No Dn Don't knowCL02 Clo taken Yes
□u
CL02RESULT Result Positive oy Negative dn Don't know
□u
Any other relevant diagnosis at OGD? GAST2SECON
No □ 0 DU D 1 Oesophagitis 02 HH 0 3
Other 05
Stricture 04
Treatment received GAST2TREAT None Dn
h2ra Dh
ppi Dp for GAST2WEEKS weeks
Eradication De
Symptoms on referral for investigation Dyspepsia / Heartburn /Reflux Dl
GAST2SYMPT Epigastric Pain ± other symptom(s) D2
Heamatemesis ± Melaena U3
Other CU
If other please specify OTHERSYMP2
(e.g. Anaemia, Dysphagia, Vomiting, Weight Loss, Early Satiety)
Date first GP consultation with symptoms this episode GPDATE2
Time from consultation to OGD 2 GPTIME2 weeks
Was the patient on concurrent Aspirin or NSAIDs NSAID2 YesD Y No Dn
Patient on AST in time from consultation to OGD 2 AST2 YesD Y No Dn
If Yes, Date start of AST (antisecretory therapy) prior to OGD 2 AST2DATE
Time from consultation to AST initiated ASTTIME2 weeks
Duration of AST prior to OGD 2 DURATION2 weeks
Which medication this episode? H2RA2 H2ra Dfor H2RAWEEKS2 weeks H2RASCRIP2
PP12 PPI Dfor PPIWEEKS2 weeks PPISCRIP2
Was treatment stepped up from an H2RA to a PPI in this time? STEPUP2 Yes D Y No D N
Was treatment stopped by GP prior to OGD 2? STOPGP2 Yes D Y No D N
If Yes.. Date stopped STOPDATE2 No. of weeks prior to OGD STOPWEEKS2




No. of (monthly) prescriptions of AST in time period from OGD 2 to cancer OGD
SCRIPTAST2
142
No. of (monthly) prescriptions of AST type H2RA ASTTYPEH2 PPI
ASTTYPEP2
Therefore, AST ASTTREAT2 NoneO N ContinuousO C Intermittent!!!] I
Time from OGD 1 to diagnosis of cancer OGD2INDEX weeks
Did the patient have another OGD prior to OGD 2 (within 3 years of Cancer OGD)
OTHEROGD2
Yes D Y No
If YeS, continue with section B
□ N
If No, go to section C
Time from OGD 2 to diagnosis of cancer OGD21NDEX weeks
Did the patient have another OGD prior to OGD 2 (within 3 years of Cancer OGD)?
OTHEROGD2
Yes D Y No D N
If YeS9 continue with section B If No, go to section C
SECTION C - SIGNIFICANT PAST HISTORY
Previous Cholecystectomy YesD Y NoD N If Yes, date
PREVCHOLE DATECHOLE
Previous Gastric Surgery YesD Y NoD N If Yes, date
PREVSURG DATESDRG
Previous upper Gl investigations more than 3 years from cancer diagnosis?
PREVINVEST
Yes □ Y No □ N
If Yes, Investigation INVEST1 Date DATE1
Investigation INVEST2 Date DATE2
Investigation INVEST3 Date DATE3






Is the patient alive ALIVE Yes
TODAYSDATE
If Yes, time since diagnosis of cancer
If No, date of death
Cause of death
Was patient alive at LIVEDFOR




Less than 1 month □ 0
1 month □ 1
6 months □ 6
1 year □ 12
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2 years D 24
If more than 2 years, number of years since diagnosis LIVEDYEARS
Did the patient undergo surgical resection? SURGERY YesDY No EH N
If Yes.. Curative intent CURE □ Palliative PALLIATIVE □







Date of birth DOB







Female □ F Postcode
First symptoms Date FIRSTSYMPT or Duration ORDURATION
On continuous AST prior to 1st GP consult? ONAST1 (N, H, P, B, E)
Number of weeks treatment TREATMENTl
Nature of symptoms as recalled NATURESYMP
Dyspepsia / Heartburn /Reflux □!
Epigastric Pain ± other symptom(s) □ 2
Heamatemesis ± Melaena □ 3
Other □ 4
If other please specify OTH ERPLEAS
(e.g. Anaemia=5, Dysphagia=6, Vomiting=7, Weight Loss=8, Early Satiety=9, Anorexia=10,
Mass=l I, Other=l2)
OTHER1ST1 OTHER1ST2 OTHER1ST3 OTHER1ST4
If bleeder, benign or worrying BLEEDERSWO (B, W)
First consultation GP Date FIRSTCONSU duration from Ist symptoms DURAT10N2R
On AST 1st GP consult to referral?
Number of weeks treatment
ONAST2 (N, H, P, B, E)
TREATMENT2
Symptoms at first consultation GP SYMPTOMSAT
Dyspepsia / Heartburn / Reflux







If other please specify OTHERPLEOl
(e.g. Anaemia=5, Dysphagia=6, Vomiting=7, Weight Loss=8, Early Satiety=t), Anorexia=IO,
Mass=l 1, Other=!2)
OTHER2ND1 OTHER2ND2 OTHER2ND3 OTHER2ND4
If bleeder, benign or worrying BLEEDERS01 (B, W)
Referral date REFERRALDA Date first seen at Hospital DATEF1RSTS
GP suspect cancer? GPSUSPECT (Y, N) Time in weeks from referral to seen at hospital
DURATION3F
On AST from referral to seen? ONAST3 (N, H, P, B, E)
Number of weeks treatment TREATMENT3
Symptoms on referral SYMPTOMSON
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Dyspepsia / Heartburn /Reflux □!
Epigastric Pain ± other symptom(s) □ 2
Heamatemesis ± Melaena □ 3
Other □ 4
If other please specify OTHERPLE02
(e.g. Anaemia=5, Dysphagia=6, Vomiting=7, Weight Loss=8, Early Satiety=0, Anorexia=IO,
Mass=l 1, Other=12)
If bleeder, benign or worrying BLEEDERS02 (B, W)
OTHER3RD1 OTHER3RD2 OTHER3RD3 OTHER3RD4
Date of cancer diagnosis DATECANCER Time in weeks from seen at hospital to diagnosis
DURATION4F
On AST from seen at hospital to cancer diagnosis? ONAST4 (N, H, P, B, E)
Number of weeks treatment TREATMENT4
Symptoms at time of cancer diagnosis SYMPTO1MS01
Dyspepsia / Heartburn /Reflux 0 1
Epigastric Pain ± other symptom(s) □ 2
Heamatemesis ± Melaena □ 3
Other □ 4
If other please specify OTHERPLE03
(e.g. Anaemia=5, Dysphagia=6, Vomiting=7, Weight Loss=8, Early Satiety=0, Anorexia=10,
Mass=l 1, Other=!2)
OTHER4THI OTHER4TH2 OTHER4TH3 OTHER4TH4






Diffuse □ Y, N




PH Gl Investigations within 3 years of diagnosis? PHGIINVEST Y, N
If yes, type of investigation? TYPEINVESI OGD, BAR, USS,
LAP
Number of OGDS? NUMBEROGDS 0,1,2,3
147
Appendix II. Oesophageal and gastric cancer staging165.
Oesophagus
Primary tumour (T)
TX primary tumour cannot be assessed
TO no evidence of primary tumour
Tis carcinoma in situ
T1 tumour invades lamina propria or submucosa
T2 tumour invades muscularis propria
T3 tumour invades adventitia
T4 tumour invades adjacent structures
Regional lymph nodes
NX regional lymph nodes cannot be assessed
NO no regional lymph node metastasis
N1 regional lymph node metastasis
Distal metastasis
MX presence of distal metastasis cannot be assessed
MO no distant metastasis
Ml distant metastasis
Staging
0 Tis NO MO
1 T1 NO MO
2a T2 NO MO
T3 NO MO
2b T1 N1 MO
T2 N1 MO
3 T3 N1 MO
T4 Any N MO




TX primary tumour cannot be assessed
TO no evidence of primary tumour
Tis carcinoma in situ
T1 tumour invades lamina propria or submucosa
T2 tumour invades muscularis propria
T3 tumour invades adventitia
T4 tumour invades adjacent structures
Lymph nodes
NO no nodal involvement
N1 involvement ofperigastric nodes within 3cm of primary
N2 involvement ofmore distant perigastric and regional nodes that are amenable
to removal at gastrectomy
N3 involvement ofmore distant intra-abdominal nodes including mesenteric,
hepato-duodenal and retropancreatic.
Distal metastasis




NO N1 N2 N3
MO Tis 0 - - - -
T1 1A IB 2 4 4
T2 IB 2 3A 4 4
T3 2 3A 3B 4 4
T4 3A 3B 4 4 4
Ml 4 4 4 4 4
This staging system was used for this thesis. There have been further
modifications 19°.
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Appendix III. ASA Classification.
Stage 1 Normally healthy.
Stage 2 Mild systemic disease
Stage 3 Severe systemic disease that limits activity; not
incapacitating
Stage 4 Incapacitating systemic disease that poses a threat to life
Stage 5 Moribund. Not expected to survive 24 hours even with
operation
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SUMMARY
Background: Upper gastrointestinal cancer carries a poor
prognosis. Although the incidence of gastric adenocarci¬
noma is falling, oesophageal adenocarcinoma is increas¬
ing. This has been attributed to an increasing prevalence
of gastro-oesophageal reflux disease, commonly treated
empirically in primary care with antisecretory drugs.
Treatment has been associated with delayed diagnosis
but it is unclear if this influences prognosis.
Aims: To ascertain the effect of antisecretory drugs on
time to diagnosis, symptoms, tumour stage and out¬
come.
Methods: A retrospective cohort study of primary care
records for 747 patients diagnosed with upper gastro¬
intestinal adenocarcinoma at South Tees NHS Trust
between 1991 and 2001.
Results: Mean time from the onset of symptoms to
diagnosis was 30 weeks. Mean and median times at the
primary care stage were longer than at the hospital
stage for both oesophageal and gastric cancer
(P < 0.0001). Patients with benign symptoms pre¬
scribed antisecretory drugs were referred later than
those not on antisecretory drugs (P < 0.0001), as were
patients with alarm symptoms (P = 0.0008). Prior use
of antisecretory drugs delayed diagnosis by 17.6 weeks
(mean) but had no effect on tumour stage at diagnosis
or survival.
Conclusion: Prior antisecretory drug therapy was
associated with delayed diagnosis of upper gastroin¬
testinal adenocarcinoma irrespective of presenting
symptoms. Concerns that delays might adversely
affect tumour stage or long-term survival were not
substantiated.
INTRODUCTION
For more than half a century the overall incidence and
mortality rates of gastric cancer have been slowly
declining1 although adenocarcinoma of the gastric
cardia is becoming more common.2-4 The incidence of
adenocarcinoma of the oesophagus is also increasing;
this has been attributed to the increasing prevalence of
gastro-oesophageal reflux.5 It is now the commonest
form of oesophageal cancer.5-7 In the UK there are often
delays in the diagnosis of oesophago-gastric cancer8, 9
Correspondence to: Dr S. Panter, South Tyneside District Hospital, Harton
Lane, South Shields, NE34 OPL, UK.
E-mail: simon.panter@sthct. nhs. uk
for reasons that are unclear. Patients may delay seeing
a doctor and referral to hospital may be deferred by a
previous history of dyspepsia11' or absence of alarm
symptoms.11 These factors influence the process leading
to endoscopy and diagnosis. In addition the empirical
use of antisecretory drugs prior to diagnosis, partic¬
ularly proton pump inhibitors (PPIs) can contribute to
the delay through the modification of symptoms and the
potential healing of early malignant ulcers.12 Also,
dyspepsia management guidelines increasingly advo¬
cate empirical therapy for Helicobacter pylori negative
patients under 55 years without alarm symptoms;11
thus people who have previously received antisecretory
drug therapy are likely to receive further prescriptions
when symptoms recur.
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AIMS
The aim of this study was to identify the patterns of
presentation of oesophago-gastric adenocarcinomas, to
ascertain the effect of prior antisecretory drug therapy
on the time to a definitive diagnosis and the effect on
symptoms, tumour stage and outcome.
PATIENTS AND METHODS
The study design was a survey of the records of all
patients with an established diagnosis of primary
oesophageal or gastric adenocarcinoma over a 10-year
period.
The study was based in the South Tees health district
of Teesside, a mixed industrial and rural area with a
catchment population of c. 300 000. Because of the
centralization of gastroenterology services it is estimated
that over 95% of all patients referred with gastrointes¬
tinal problems are seen at one hospital, the James Cook
University Hospital. This enabled central access to
patient records, and endoscopy and pathology reports.
Both primary and secondary care records were
accessed.
To meet the inclusion criteria patients had to have a
definitive cancer diagnosis established within the pop¬
ulation area, for the first time, in the 10 years to April
2001.
Patients were initially identified from the computerized
pathology database. The list obtained was cross-refer¬
enced with the regional cancer registry (Northern and
Yorkshire Cancer Registry and Information Service) and
the hospital's own cancer records to ensure complete¬
ness and accuracy of the patient cohort. The identified
patients' primary care records were reviewed at their
general practices or, where the patients were dead,
retrieved from the central registry of Tees and North
Yorkshire Health Authorities. These were reviewed to
record demographic characteristics and to detail the
diagnostic pathway leading to the definitive diagnosis
and eventual outcomes. These details included the
timings of the onset of symptoms, first General Practi¬
tioner (GP) consultation with new onset symptoms and
the timings of referral and investigations. Details about
the prescribing of antisecretory drugs prior to investi¬
gation were also recorded and the hospital records
reviewed for endoscopy findings, including the endos¬
copist, number of biopsies taken, tumour stage at
diagnosis and long-term outcome.
Statistics
Data handling and analysis was performed using the Epi
InfoIM epidemiological database and statistical analysis
package (US Dept. of Health and Human Services Center
for Disease Control and Prevention, Atlanta, GA, USA).
The accuracy of data entry was optimized by using
double data entry and cross checking. Data were
analysed using parametric methods for normally distri¬
buted continuous data (t-test, anova) and nonparamet-
ric methods (^2, Kruskal-Wallis) for categorical data and
non-normally distributed continuous data. Results were
considered to be statistically significant with P-values
<0.05 (95% confidence limits).
RESULTS
A total of 747 patients were identified of whom 685
(92%) were included in the study. Table 1 and Figure 1
details patient numbers.
REFERRAL PATTERNS
The mean time from first symptoms, as recorded in the
notes from the patients' history, to diagnosis, was
30 weeks (median 14, range 1-428). Compared to
patients with gastric cancer those with oesophageal
cancer took longer to present to their GP (P = 0.003)
and longer to be seen in secondary care once referred
(P = 0.03). All the other time periods (time to be
referred, time to definitive diagnosis) showed no statis¬
tically significant differences. The mean and median time
durations during which the patient remained under
primary care management only was double the hospital
phase times, for both oesophageal and gastric cancer
(P < 0.0001). There were no significant differences
between the time periods the patient remained in
primary care alone or in hospital management for either
oesophageal or gastric cancer.
Details are shown in Table 1.
Symptoms
Figure 2 shows the symptoms as recorded in the GP and
hospital notes at the various stages in the diagnostic
process. Initially only 50% of patients had alarm
symptoms (i.e. anaemia/dysphagia/weight loss/vomit¬
ing). By the time of referral this had risen to 71% and at
diagnosis to 78%.
© 2004 Blackwell Publishing Ltd, Aliment Pharmacol Ther 19, 981-988
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Figure 1. Details of study cohort.
Empirical treatment
Overall, of the 685 patients with adenocarcinoma
47.7% had antisecretory drug treatment between the
onset of symptoms and diagnosis. In 66.8% this was
initiated at the first GP visit. Patients with oesophageal
adenocarcinoma were more likely than patients with
gastric adenocarcinoma to be taking antisecretory
drugs prior to their first GP consultation with new
onset symptoms (13.6% vs. 6.2%) (P = 0.002).
Patients were predominantly prescribed PPIs although
33.9% were on a H2RA beforehand. There was no
significant difference between males and females in
relation to rates of antisecretory drugs prescribing at
any stage. Details are shown in Table 1.
Antisecretory drug prescribing and time to diagnosis of
cancer
An increase in the time to diagnosis was associated with
the use of antisecretory drugs at all stages (Table 1).
The time interval before referral from primary care to
hospital was significantly longer in those prescribed
antisecretory drugs compared with those who were not
prescribed these. This was irrespective of the presenting




























□ Epigastric pain (benign)
□ Bleeders
□ Anaemia/dysphagia/weight loss
Figure 2. Symptoms as recorded in the General Practitioner (GP) notes at the various stages of the 'diagnostic pathway'. AST.
antisecretory drug therapy.
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symptoms except for those presenting with haemate-
mesis/melaena. For those treated with antisecretory
drugs prior to gastroscopy the mean time from their first
GP visit with new onset symptoms to diagnosis was
increased by 17.6 weeks (P < 0.001).
Effect of antisecretory drug therapy on symptoms
The number of patients with alarm symptoms at each
stage of the diagnostic pathway, in relation to whether
or not they were prescribed antisecretory drugs is
shown in Figure 2. In total 339 (49.5%) of patients had
benign symptoms at their first GP consultation; of these
175 (51.6%) were given antisecretory drugs. For
patients with alarm symptoms 20.2% were prescribed
antisecretory drugs. Thus patients with more benign
sounding symptoms were more likely to have been
prescribed antisecretory drugs (P < 0.0001).
Patients with benign symptoms prescribed antisecre¬
tory drugs (n = 175) were referred later than patients
with benign symptoms not given antisecretory drugs
(n = 164) (mean 16.4 vs. 5.54 weeks, median 8 vs.
1 weeks, P < 0.0001). Similarly, patients with alarm
symptoms were referred later if antisecretory drugs had
been prescribed (5.6 vs. 1.8 weeks, median 1 vs. 0,
P = 0.0008). Thus the use of antisecretory drugs was
associated with a longer time to referral. During this
period more patients developed alarm symptoms. How¬
ever, 98.6% of patients with alarm symptoms at the first
GP consultation and who were prescribed antisecretory
drugs still had alarm symptoms by the time of hospital
consultation. This suggests that the use of antisecretory
drugs did not change alarm symptoms to benign
sounding symptoms.
Effect of antisecretory drug therapy on tumour stage at
diagnosis
Staging data using the TNM classification13 was avail¬
able for 477 patients (70% of total). Of these 287
underwent surgery. Treatment with antisecretory drugs
was not associated with the tumour stage at diagnosis for
either oesophageal or gastric adenocarcinoma (P = 0.49
and P = 0.31 respectively) as shown in Table 1.
Effect of antisecretory drug therapy on survival
The effects of empirical antisecretory drugs on survi¬
val (Kaplan-Meier) following diagnosis are shown for
both oesophageal and gastric adenocarcinoma in
Figure 3. No significant differences were observed
between the two groups except for gastric adenocar¬
cinoma where patients with stage Ilia disease had a
worse prognosis with prior empirical antisecretory
drugs.
DISCUSSION
Upper gastrointestinal cancer carries a poor prognosis in
Western countries where the incidence of oesophageal
adenocarcinoma is increasing5 on a background of
falling rates for gastric adenocarcinoma.1 This change
has been attributed to the increasing prevalence of
gastro-oesophageal reflux disease,14 a condition com¬
monly treated by empirical antisecretory drugs. PPIs are
now the drugs of choice for treating symptomatic reflux
and their efficacy means that increased prescribing of
these powerful acid suppressants is a modern phenom¬
enon seen in many western countries.13•16 Concern
about these drugs masking cancer or delaying diagno-
sis o. 12, 3/ is therefore important if the net effect is a
worse prognosis.
Symptoms are the major influence on the timing and
presentation of patients to their GP and subsequent
referral for investigation. The vast majority of dyspeptic
patients in the 'at risk' age group will have benign
disease, even if some of their symptoms are 'worrying',
as symptoms are a poor predictor of pathology.18-20
Some patients are also very elderly and would poten¬
tially not be suitable for surgery even if diagnosed early.
However the mean age was 70.3 years at diagnosis and
we can find no evidence that age per se delayed referral.
A limitation of this study is its retrospective nature and
that only those with cancer were studied rather than
the dyspeptic population as a whole. However, the fact
that patients with oesophageal adenocarcinoma took
longer to present to their GP suggested that they were
not concerned by their symptoms until relatively later.
These patients were also more likely to have been on
antisecretory drugs previously, compared with those
with gastric adenocarcinoma, with 26% of the oeso¬
phageal adenocarcinoma patients on antisecretory drug
therapy prior to their first GP consultation having a past
history of Barrett's oesophagus.
This study confirms previous work showing that
patients given antisecretory drugs endure a delay to a
definitive morphological diagnosis. Patients given anti¬
secretory drugs on their first visit to the GP had a longer
© 2004 Blackwell Publishing Ltd, Aliment Pharmacol Ther 19, 981-988
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Figure 3. Kaplan-Meier survival curves for oesophageal and gastric adenocarcinoma and the effect of antisecretory drug therapy.
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time to diagnosis at all stages of the process but the
longest delay occurred because patients previously
prescribed antisecretory drugs did not seek a further
medical opinion and when they did, the GP was likely to
restart the antisecretory drugs rather than refer for
investigation. Patients with worrying symptoms
received antisecretory drugs less frequently and were
referred quickly compared to those with more dyspeptic
symptoms. In many cases the delay was many months
during which time it might be assumed that the tumour
would progress significantly and worsen both the stage
of the disease at diagnosis and long-term survival. The
results indicate this did not happen. Those patients with
early stage disease (early gastric cancer or stage I
disease) had the longest period on treatment but were
still 'early' when eventually diagnosed.
The reasons for this are probably explained by the
natural history of upper gastrointestinal adenocarcino¬
ma. In the oesophagus the disease spreads relatively
early21 and even those patients referred quickly are
likely to have disease that has infiltrated the lymphatics,
making curative resection less likely. Thus delays
resulting from prior antisecretory drugs are unlikely to
affect prognosis. In relation to stomach cancer, patients
with early disease were more likely to have benign
symptoms and more likely to have been prescribed
antisecretory drugs. Tumour-doubling time is long in
early stage disease21"2' making a delay less critical in
terms of tumour stage at diagnosis. Patients with alarm
symptoms have more advanced disease3 associated with
a rapid tumour doubling time.23 In this study patients
with alarm symptoms were less likely to receive
antisecretory drugs and were referred more quickly.
Thus those patients presenting with mucosal disease
and benign sounding symptoms in primary care still
had mucosal disease when diagnosed at gastroscopy
despite many months' delay.
In conclusion, this study confirmed that empirical
antisecretory drug therapy was associated with a
significant delay in the definitive diagnosis but that this
did not affect the tumour stage at diagnosis. The long-
term outcomes were identical in those who had been
prescribed antisecretory drugs prior to diagnosis and
those who had not. Withholding antisecretory drugs
prior to investigation may accelerate a definitive
diagnosis but is not likely to affect the eventual
outcome. We cannot recommend routinely treating 'at
risk' patients with antisecretory drugs prior to gastros¬
copy, as patients will still perceive this as a delay.
However this paper does support the concept that such
a delay has little significance, as outcome is poor in both
groups. These findings have important clinical, man¬
agement and medico-legal implications.
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Brief reports
Urgent cancer referral guidelines:
a retrospective cohort study of referrals
for upper gastrointestinal adenocarcinoma
Simon ] Panter, Mike G Bramble, Hilda O'Flanagan and A Pali S Hungin
SUMMARY
Dyspepsia in primary care is common and guidelines indicate
that patients with alarm symptoms, as defined by the urgent
cancer referral guidelines, should be investigated by
gastroscopy. The specificity and sensitivity of alarm symptoms
is poor and only a small percentage ofpatients will turn out to
have malignant disease. This primary care study shows that
employing current guidelines will identfy only 72% ofpatients
at their initial visit to a general practitioner, but thisfigure
could be increased to 86% f the guidelines included patients
with weight loss or anaemia in the absence of dyspepsia. Past
performance indicates that the majority ofpatients with the
commonest symptom complex were not referred quickly and less
than hafwere seen within 4 weeks.
Keywords: adenocarcinoma; diagnosis; gastrointestinal diseases;
referral; uppergastrointestinal tract.
Introduction
N The NHS Cancer plan,1 the United Kingdom
government introduced urgent cancer referral guidelines
(the '2-week rule') to ensure that everyone with suspected
cancer would be referred to a specialist by their general
practitioner (GP) and seen within 2 weeks of the referral
date.2 In June 2000 guidelines were issued to general prac¬
titioners highlighting the symptom complexes experienced
by patients with upper gastrointestinal (UGI) malignancy,3
but the evidence base is acknowledged to be poor4 5 and
data from hospital studies suggest that nearly
all patients with UGI malignancy will have 2-week rule
symptoms.6
The aim of this study was to examine referral practice
and outcome, utilising the 2-week rule criteria for all
patients diagnosed as having UGI adenocarcinoma during
the 10-year period 1991-2001 in order to identify what pro¬
portion of patients fulfilled the 2-week rule criteria, and to
determine how primary care had managed these patients
before referral.
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Method
All patients with UGI adenocarcinoma (excluding pancreatic)
diagnosed in the South Tees Health Authority area, where a
single endoscopy unit serves the entire population, were
identified from the hospital computerised pathology data¬
base for the period April 1991-April 2001. Completeness of
the data was verified with the regional cancer registry
(NYCRIS). Primary care records were reviewed with respect
to the government's urgent cancer referral guidelines and
data analysed using parametric methods for normally
distributed continuous data (f-test, ANOVA) and non-para¬
metric methods (x2, Kruskal-Wallis) for categorical and
non-normally distributed data.
Results
A total of 747 patients were identified, of whom 685 (92%)
were included in the study. Of those excluded, the majority
(35) did not have a primary gastric or oesophageal adeno¬
carcinoma. A total of 494 (72.1%) patients fulfilled the
2-week rule criteria in terms of symptoms at the initial con¬
sultation with the GP (Table 1). The largest group of patients
fulfilling the 2-week rule criteria were those aged 55 years
and over, with dyspepsia or epigastric pain for less than
1 year, with continuous symptoms since onset (n = 244,
40.1%). The mean time to referral was 6.7 weeks (range
within 1-174 weeks) with 68 (27.9%) being referred immed¬
iately to secondary care, increasing to 119 (48.8%) by
4 weeks. The second largest group comprised patients with
British Journal of General Practice, August 2004 611
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dysphagia (n = 115) of whom 80 (69.6%) had this as the
main presenting symptom. Dyspepsia associated with
anaemia accounted for 14 (3.8%) patients. Nine patients
(2.4%) had an epigastric mass. Twenty patients presented
with acute bleeding. Patients referred quickly from primary
care were seen more quickly in hospital (Spearman rank
correlation coefficient = 0.79, P<0.05). Males were more
likely to fit the 2-week rule (P = 0.022) and females were sig¬
nificantly older (P<0.001).
There were 191 (27.9%) patients who did not fit the major
urgent referral criteria for suspected UGI malignancy at the
first consultation in primary care (Table 2). The mean time
to referral was 7.1 weeks (range within 1-137 weeks) with
75 (39.3%) being referred immediately to secondary care,
Table 1. Details of patients' symptoms shown along with the time taken for the general practitioner (GP) to refer the patient to a specialist or
open access gastroscopy.
Mean time from GP % referred Mean time from
consultation to referral within referral to appointment % seen within % seen within
2-week rule criteria (mutually exclusive) in weeks (range) 4 weeks in weeks (range) 2 weeks 4 weeks
Total (n = 494)a 6.7 (1-174) 65.4 2.6 (1-30) 46.4 71.9
Aged >55 years with dyspepsia/heartburn/
reflux <1 year duration (n = 244)
10.8 (1-174) 48.8 2.8 (1-17) 39.3 66.8
Aged >55 years with Gl bleeding first symptoms 0.2 (1-5)
dyspepsia/reflux/epigastric pain (n = 29)
96.6 0.6 (1-9) 89.7 93.1
Dysphagia (n = 115) 2.4 (1-120) 86.1 2.5 (1-18) 44.3 78.3
Dyspepsia or epigastric pain
with weight loss (n = 49)
1.6 (1-10) 83.7 3.0 (1-22) 46.9 67.3
Dyspepsia or epigastric pain with past
history of gastric surgery/
Barretts oesophagus/dysplasia (n = 23)
6.9 (1-24) 43.5 3.1 (1-9) 43.5 60.9
Dyspepsia or epigastric pain
with anaemia (n = 14)
5.8 (1-30) 71.4 2.5 (1-11) 64.3 78.6
Dyspepsia or epigastric pain
with vomiting (n = 11)
6.6 (1-34) 54.5 3.7 (1-30) 72.7 72.7
Palpable mass (n = 9) 0.1 (1) 100 1.0 (1-3) 66.7 100
aMen n = 338 (68.4%), women n = 156 (31.6%). Gl = gastrointestinal.
Table 2. Details of patients' symptoms shown along with the time taken for the general practitioner (GP) to refer the patient to a specialist or
open access gastroscopy.
Mean time from GP
consultation to referral











Total (n = 191)a 7.1 (1-137) 62.3 2.8 (1-18) 49.2 69.6
Aged <55 years with dyspepsia/heartburn
/reflux or epigastric pain (n = 31)
17.7 (1-137) 32.3 4.1 (1-18) 32.3 61.3
Aged >55 years with dyspepsia or heartburn/
reflux or epigastric pain >1 year (n = 16)
26.9 (1-126) 12.5 4.6 (1-13) 37.5 43.8
Weight loss, no upper Gl symptoms (n = 53) 2.5 (1-20) 69.8 2.4 (1-16) 45.3 75.5
Anaemia, no upper Gl symptoms (n = 31) 2.8 (1-40) 77.4 2.6 (1-13) 48.4 67.7
Dyspepsia or epigastric pain
with anorexia (n = 15)
4.1 (1-14) 60.0 1.7 (1-8) 66.7 86.7
Fatigue and/or lethargy (n = 15) 4.0 (3-5) 80.0 1.5 (1-3) 53.3 73.3
Chest pain and/or breathlessness (n = 10) 3.0 (1-21) 80.0 3.0 (1-12) 60.0 60.0
Collapse (n = 9) 1.1 (1-5) 88.9 1.0 (1-5) 77.8 77.8
Nausea and vomiting (n = 8) 1.3 (1-3) 100.0 3.0 (1-18) 75.0 75.0
Lower abdominal pain (n = 3) 3.0 (1-5) 66.7 1.0 (1-3) 66.7 100.0
aMen n =113 (62.0%), women n =78 (38.0%). Gl = gastrointestinal.
HOW THIS FITS IN
What do we know?
Dyspepsia in primary care is common
and recent guidelines indicate that patients
with alarm symptoms should be investigated.
What does this paper add?
This primary care study shows that employing current
guidelines will identify only 72% of patients at their first visit to
a general practitioner, but if the guidelines included patients
with weight loss or anaemia in the absence of dyspepsia this
figure could be increased to 86%.
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increasing to 119 (62.3%) by 4 weeks. Almost half (49.2%)
were seen within 2 weeks and 69.6% by 4 weeks. The
majority of these patients subsequently developed symp¬
toms fitting referral criteria. There were 53 patients (16.8%)
with weight loss but no UGI symptoms at initial
consultation. Patients without UGI symptoms but with
anaemia accounted for 31 patients (9.8%). There were 14
emergency admissions with severe anaemia but no Gl
symptoms. Thirty-one patients aged 55 years or under
presented with benign symptoms (dyspepsia or epigastric
pain alone). Almost all (93.5%) had symptoms for less than
1 year and 45.2% had symptoms for less than 1 month
prior to consulting their GR Time to referral ranged from
1-137 weeks (mean = 17.7 weeks) but only 6 patients
(19.4%) had worrying symptoms at the time of referral.
Discussion
The aim of this study was to assess the robustness of the
current referral guidelines, viewed from the primary care
perspective. At present, the evidence for identifying
2-week rule patients comes from hospital-based studies
based on symptoms present in patients found to have
malignancy on gastroscopy.4'5 The percentage of cancer
patients presenting with alarm symptoms in primary care
is estimated to be close to 100%, but this is largely based
on symptoms at endoscopy.6'7 It is clear that, prior to the
new guidelines, less than half of all patients with alarm
symptoms were referred within 4 weeks, indicating a high
referral threshold.
In this series the largest group not fulfilling the new UGI
urgent referral guidelines were patients with weight loss
but no UGI symptoms (n = 53) or patients below 55 years
of age with benign symptoms (n = 31). Only a third of
patients in the latter group were referred by 2 weeks and
one-third seen by 2 weeks. Although weight loss or
anaemia without Gl symptoms represented 44% of those
not meeting the guidelines GPs felt that UGI malignancy
was a possibility and hence referred patients with the same
degree of urgency as those with 2-week rule criteria. Our
results indicate that younger patients (45-55 years of age)
and those with early disease and simple dyspepsia will be
disadvantaged by the new guidelines.8'9 Unexplained
weight loss or iron deficiency anaemia in the absence of
UGI symptoms account for 12.3% of patients and should
be considered for inclusion in any new guidance. Elderly
patients with new onset dyspepsia should be followed up
closely in primary care in case alarm symptoms develop,
and referred urgently if symptoms fail to settle. Clearly, this
study lacks the denominator to be sure that adopting these
new strategies would not lead to an increase in urgent
referrals with little improvement in the overall delay in diag¬
nosis. Even allowing for this, our findings indicate that the
current referral guidelines will not identify one in seven
patients with UGI adenocarcinoma at their initial GP visit.
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